Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms.
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE.
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.
Purplish or brownish red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues. When the size of the discolorization is >2-3 cm it is generally called Ecchymoses (ECCHYMOSIS).
A systemic non-thrombocytopenic purpura caused by HYPERSENSITIVITY VASCULITIS and deposition of IGA-containing IMMUNE COMPLEXES within the blood vessels throughout the body, including those in the kidney (KIDNEY GLOMERULUS). Clinical symptoms include URTICARIA; ERYTHEMA; ARTHRITIS; GASTROINTESTINAL HEMORRHAGE; and renal involvement. Most cases are seen in children after acute upper respiratory infections.
The number of PLATELETS per unit volume in a sample of venous BLOOD.
Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.
Surgical procedure involving either partial or entire removal of the spleen.
A subnormal level of BLOOD PLATELETS.
A family of membrane-anchored glycoproteins that contain a disintegrin and metalloprotease domain. They are responsible for the proteolytic cleavage of many transmembrane proteins and the release of their extracellular domain.
A severe, rapidly fatal reaction occurring most commonly in children following an infectious illness. It is characterized by large, rapidly spreading skin hemorrhages, fever, or shock. Purpura fulminans often accompanies or is triggered by DISSEMINATED INTRAVASCULAR COAGULATION.
Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.
A syndrome that is associated with microvascular diseases of the KIDNEY, such as RENAL CORTICAL NECROSIS. It is characterized by hemolytic anemia (ANEMIA, HEMOLYTIC); THROMBOCYTOPENIA; and ACUTE RENAL FAILURE.
Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.
The co-occurrence of pregnancy and a blood disease (HEMATOLOGIC DISEASES) which involves BLOOD CELLS or COAGULATION FACTORS. The hematologic disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS.
Immunizing agent containing IMMUNOGLOBULIN G anti-Rho(D) used for preventing Rh immunization in Rh-negative individuals exposed to Rh-positive red blood cells.
Extravasation of blood into the skin, resulting in a nonelevated, rounded or irregular, blue or purplish patch, larger than a petechia.
Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.
A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
Purplish or brownish red discoloration of the skin associated with increase in circulating polyclonal globulins, usually GAMMA-GLOBULINS. This syndrome often occurs on the legs of women aged 20 to 40 years.
I'm sorry for any confusion, but the term "Oklahoma" is a geographical location and not a medical condition or term, therefore it doesn't have a medical definition. It is a state in the South Central region of the United States.
Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.
The process of generating thrombocytes (BLOOD PLATELETS) from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW via the MEGAKARYOCYTES. The humoral factor with thrombopoiesis-stimulating activity is designated THROMBOPOIETIN.
ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.
Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Antibodies obtained from a single clone of cells grown in mice or rats.
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors.
Adrenal cortex hormones are steroid hormones produced by the outer portion of the adrenal gland, consisting of glucocorticoids, mineralocorticoids, and androgens, which play crucial roles in various physiological processes such as metabolism regulation, stress response, electrolyte balance, and sexual development and function.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
An appreciable lateral deviation in the normally straight vertical line of the spine. (Dorland, 27th ed)
Biologically active substances whose activities affect or play a role in the functioning of the immune system.
The return of a sign, symptom, or disease after a remission.
Bleeding or escape of blood from a vessel.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
A disorder characterized by procoagulant substances entering the general circulation causing a systemic thrombotic process. The activation of the clotting mechanism may arise from any of a number of disorders. A majority of the patients manifest skin lesions, sometimes leading to PURPURA FULMINANS.
Antibodies from an individual that react with ISOANTIGENS of another individual of the same species.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
The residual portion of BLOOD that is left after removal of BLOOD CELLS by CENTRIFUGATION without prior BLOOD COAGULATION.
Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)
A PREDNISOLONE derivative with similar anti-inflammatory action.
The presence of free HEMOGLOBIN in the URINE, indicating hemolysis of ERYTHROCYTES within the vascular system. After saturating the hemoglobin-binding proteins (HAPTOGLOBINS), free hemoglobin begins to appear in the urine.
Disease having a short and relatively severe course.
A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed)
Platelet membrane glycoprotein complex essential for normal platelet adhesion and clot formation at sites of vascular injury. It is composed of three polypeptides, GPIb alpha, GPIb beta, and GPIX. Glycoprotein Ib functions as a receptor for von Willebrand factor and for thrombin. Congenital deficiency of the GPIb-IX complex results in Bernard-Soulier syndrome. The platelet glycoprotein GPV associates with GPIb-IX and is also absent in Bernard-Soulier syndrome.
Antibodies produced by a single clone of cells.
Infection of the spleen with species of MYCOBACTERIUM.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Bleeding from the nose.
Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
The flowing of blood from the marginal gingival area, particularly the sulcus, seen in such conditions as GINGIVITIS, marginal PERIODONTITIS, injury, and ASCORBIC ACID DEFICIENCY.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Serum globulins that migrate to the gamma region (most positively charged) upon ELECTROPHORESIS. At one time, gamma-globulins came to be used as a synonym for immunoglobulins since most immunoglobulins are gamma globulins and conversely most gamma globulins are immunoglobulins. But since some immunoglobulins exhibit an alpha or beta electrophoretic mobility, that usage is in decline.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed)
Inflammation of any part of the KIDNEY.
Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
Disorders of the blood and blood forming tissues.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A syndrome of HEMOLYSIS, elevated liver ENZYMES, and low blood platelets count (THROMBOCYTOPENIA). HELLP syndrome is observed in pregnant women with PRE-ECLAMPSIA or ECLAMPSIA who also exhibit LIVER damage and abnormalities in BLOOD COAGULATION.
Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.
Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.
A group of interstitial lung diseases with no known etiology. There are several entities with varying patterns of inflammation and fibrosis. They are classified by their distinct clinical-radiological-pathological features and prognosis. They include IDIOPATHIC PULMONARY FIBROSIS; CRYPTOGENIC ORGANIZING PNEUMONIA; and others.
A nonspecific term used to denote any cutaneous lesion or group of lesions, or eruptions of any type on the leg. (From Stedman, 25th ed)
An encapsulated lymphatic organ through which venous blood filters.
A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
'Splenic diseases' refer to a range of medical conditions that affect the structure, function, or integrity of the spleen, leading to various symptoms and potential complications such as anemia, infection, or abdominal pain.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Elements of limited time intervals, contributing to particular results or situations.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.
Hydrazines are organic compounds containing the functional group R-NH-NH2, where R represents an organic group, and are used in pharmaceuticals, agrochemicals, and rocket fuels, but can be highly toxic and carcinogenic with potential for environmental damage.
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
Reproducible depletion of CD4+ lymphocytes below 300 per cubic millimeter in the absence of HIV infection or other known causes of immunodeficiency. This is a rare, heterogeneous syndrome and does not appear to be caused by a transmissible agent.
Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both.
A characteristic symptom complex.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A protein present in the cell wall of most Staphylococcus aureus strains. The protein selectively binds to the Fc region of human normal and myeloma-derived IMMUNOGLOBULIN G. It elicits antibody activity and may cause hypersensitivity reactions due to histamine release; has also been used as cell surface antigen marker and in the clinical assessment of B lymphocyte function.
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
An integrin beta subunit of approximately 85-kDa in size which has been found in INTEGRIN ALPHAIIB-containing and INTEGRIN ALPHAV-containing heterodimers. Integrin beta3 occurs as three alternatively spliced isoforms, designated beta3A-C.
Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS).
Antiphospholipid antibodies found in association with systemic lupus erythematosus (LUPUS ERYTHEMATOSUS, SYSTEMIC;), ANTIPHOSPHOLIPID SYNDROME; and in a variety of other diseases as well as in healthy individuals. The antibodies are detected by solid-phase IMMUNOASSAY employing the purified phospholipid antigen CARDIOLIPIN.
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.
The presence of antibodies directed against phospholipids (ANTIBODIES, ANTIPHOSPHOLIPID). The condition is associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses. In pregnancy it can cause abortion. Of the phospholipids, the cardiolipins show markedly elevated levels of anticardiolipin antibodies (ANTIBODIES, ANTICARDIOLIPIN). Present also are high levels of lupus anticoagulant (LUPUS COAGULATION INHIBITOR).
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Repetitive withdrawal of small amounts of blood and replacement with donor blood until a large proportion of the blood volume has been exchanged. Used in treatment of fetal erythroblastosis, hepatic coma, sickle cell anemia, disseminated intravascular coagulation, septicemia, burns, thrombotic thrombopenic purpura, and fulminant malaria.
The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.

Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. (1/511)

A 72-year-old female with idiopathic thrombocytopenic purpura (ITP) complained of severe chest pain. Electrocardiography showed ST-segment depression and negative T wave in I, aVL and V4-6. Following a diagnosis of acute myocardial infarction (AMI), urgent coronary angiography revealed 99% organic stenosis with delayed flow in the proximal segment and 50% in the middle segment of the left anterior descending artery (LAD). Subsequently, percutaneous transluminal coronary angioplasty (PTCA) for the stenosis in the proximal LAD was performed. In the coronary care unit, her blood pressure dropped. Hematomas around the puncture sites were observed and the platelet count was 28,000/mm3. After transfusion, electrocardiography revealed ST-segment elevation in I, aVL and V1-6. Urgent recatheterization disclosed total occlusion in the middle segment of the LAD. Subsequently, PTCA was performed successfully. Then, intravenous immunoglobulin increased the platelet count and the bleeding tendency disappeared. A case of AMI with ITP is rare. The present case suggests that primary PTCA can be a useful therapeutic strategy, but careful attention must be paid to hemostasis and to managing the platelet count.  (+info)

Usefulness of thrombopoietin in the diagnosis of peripheral thrombocytopenias. (2/511)

BACKGROUND AND OBJECTIVE: Thrombocytopenia of peripheral origin is basically due to platelet destruction or splenic sequestration. Thrombopoietin (TPO) regulates platelet production stimulating megakaryocyte proliferation and maturation. The evaluation of TPO levels may be a useful tool in the diagnosis of thrombocytopenias of unknown origin. We tried to determine the value of TPO levels in some thrombocytopenias classically considered as peripheral. DESIGN AND METHODS: Serum TPO levels and platelet counts were measured in 32 thrombocytopenic patients with liver cirrhosis (LC) and 23 with chronic hepatitis C (CHC) viral infection, in 54 patients with a clinical and serological diagnosis of autoimmune thrombocytopenic purpura (AITP), and in 88 patients infected with the human immunodeficiency virus (HIV). RESULTS: Patients with LC, AITP and HIV had lower platelet counts than patients with CHC. The degree of thrombocytopenia did not, however, correlate with the TPO levels. HIV infected patients (246+/-304 pg/mL) and AITP patients (155+/-76 pg/mL) had higher TPO levels than controls (121+/-58 pg/mL). TPO levels in patients with CHC (125+/-40 pg/mL) did not differ from those in control subjects, but were slightly decreased in patients with LC (104+/-56 pg/mL). INTERPRETATION AND CONCLUSIONS: Reduced TPO production could be involved in the development of thrombocytopenia in LC patients, but not in patients with early stages of CHC viral infection. HIV and AITP patients had slightly raised levels of TPO. As TPO levels are normal or slightly increased in most peripheral thrombocytopenias, these data alone are not sufficient to distinguish the different types of peripheral thrombocytopenia. They may, however, be a useful tool for differentiating some central and peripheral thrombocytopenias.  (+info)

The incidence of idiopathic thrombocytopenic purpura in adults increases with age. (3/511)

With the aim of determining the incidence of idiopathic thrombocytopenic purpura (ITP) in adults, we searched all adult ITP patients diagnosed from April 1, 1973 to December 31, 1995 in the County of Funen in Denmark. This county comprises 9% of the total Danish adult population. A total of 221 patients fulfilled the inclusion criteria, yielding an annual standardized incidence rate of 2.68 per 100,000. The median age of the patient population was 56 years, and the female to male ratio was 1.7. Changing the platelet count cut-off point from 100 x 10(9)/L to 50 x 10(9)/L changed the incidence rate to 2.25 per 100,000. Comparing patients less and more than 60 years old, the incidence rate more than doubled and the sex difference was eliminated in the older age group. These two age groups were almost identical regarding platelet count at diagnosis and number of asymptomatic cases. The incidence rate increased in the study period. This increase in particular involved asymptomatic patients and old males who were both symptomatic or not symptomatic. Including additional patients identified by a questionnaire study of the contribution from the primary care physicians and the practicing specialists in the second half of the study period, a reliable estimate of the annual ITP incidence in Danish adults, using a platelet concentration cut-off point of 50 x 10(9)/L, is 3.2 per 100, 000 persons.  (+info)

Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine. (4/511)

An 8-month-old male with X-linked lymphoproliferative disease underwent an unrelated, partially matched (with major mismatch at DR locus), cord blood stem cell transplant. Four months following the transplant, he developed immune thrombocytopenia with hemolytic anemia (Evans syndrome). He received multiple courses of intravenous immunoglobulin, anti-Rh D immunoglobulin, a pulse of high-dose corticosteroids and cyclosporine with some improvement of hemolytic anemia, but no improvement of the thrombocytopenia. Addition of vincristine, resulted in long-term resolution of thrombocytopenia and anemia. No major toxicity was observed during treatment. Vincristine should be considered as a treatment for refractory immune thrombocytopenia after hematopoietic stem cell transplantation.  (+info)

Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation. (5/511)

A 46-year-old white male with small cell lung cancer (SCLC) limited to the thorax developed autoimmune thrombocytopenic purpura (AITP), following a cyclophosphamide, paclitaxel and G-CSF-containing regimen for peripheral blood stem cell (PBSC) mobilization. AITP associated with small or non-small cell lung cancer has been reported. We considered that the AITP in this case may be a part of paraneoplastic syndrome, which is frequently seen in patients with SCLC. The patient received HDC and autologous PBSC transplantation (APBSCT) for SCLC and the AITP resolved following transplantation, thus supporting the concept of HDC + APBSCT for the treatment of autoimmune diseases.  (+info)

Subdural haematoma in a patient with immune thrombocytopenic purpura. (6/511)

A patient with bilateral subdural haematomas in association with idiopathic thrombocytopenic purpura is documented. She was managed successfully with platelet rich plasma and immunosuppressive therapy with steroids.  (+info)

Interferon treatment of chronic hepatitis C in patients cured of pediatric malignancies. (7/511)

BACKGROUND AND OBJECTIVE: Chronic hepatitis C was a frequent complication in patients treated for malignancy until the introduction of anti-HCV screening tests for blood donors. The association between chronic hepatitis C and progression to cirrhosis and hepatocellular carcinoma has been reported in about 20% and 5% of patients, respectively, within 20-30 years of infection. In adult patients, interferon has proved to be effective in decreasing the abnormal values of transaminases and the level of HCV viremia. Our purpose was to assess efficacy of and tolerance to interferon in a group of young patients who had acquired HCV infection during a period of chemotherapy. DESIGN AND METHODS: Interferon-a (IFN) was administered to 26 adolescents and young adults (13 males, age range 17-36 years; median age 24) with chronic hepatitis C, including 4 with hepatitis B virus co-infection, who had been treated for leukemia or solid tumor 5 to 19 years before joining this trial. Patients were treated with natural IFN alpha at a dose of 4 MU/m(2) thrice weekly for 12 months and followed up for another 6 months thereafter. RESULTS: Nine patients stopped treatment during the first 6 months because of side effects (2 cases) or lack of response. At the end of the trial, 8 (31%) cases had responded, with alanine amino-transferase normalization and clearance of hepatitis C virus (HCV) RNA. A sustained response was only documented in 15% of cases, however, irrespective of any hepatitis B virus co-infection. The 2 patients with HCV genotype 2 were both responders, whereas only 8% of those with genotype 1 responded. INTERPRETATION AND CONCLUSIONS: These data show that the efficacy of IFN in this series of young patients is similar to that reported for otherwise healthy adults with hepatitis C. Patients with genotype 2 are strong candidates for IFN treatment while other therapeutic strategies should be designed for patients with HCV genotype 1.  (+info)

Laparoscopic splenectomy for immune thrombocytopenic purpura--long-term result of 40 laparoscopic splenectomies. (8/511)

Laparoscopic surgery has recently extended its indications and it has also become an acceptable surgical approach for splenectomy. In the last five years, we have performed 40 laparoscopic splenectomies for immune thrombocytopenic purpura. Thirty-five patients were female and 5 patients were male. The mean age was 34, varying from 17 to 56. After learning to perform laparoscopic splenectomy with five ports, we are now usually using three or four ports in a right lateral kidney position. There was no case of conversion to exploratory laparotomy. The mean hospital stay was 7 days. There was no perioperative mortality; but in 2 cases we had postoperative subphrenic abscesses which were successfully managed by catheter drainage. Since undergoing laparoscopic splenectomy, 28 patients (70%) were weaned effectively from their steroid medications. Eight patients (20%) have been on small doses of steroid, and 4 patients (10%) have been on the same doses of steroid with no response. The patient group with rapidly increasing platelet count after splenectomy showed a statistically significant relation with the complete response group (p < 0.001). Laparoscopic splenectomy is a safe and reasonable operative procedure for patients with immune thrombocytopenic purpura.  (+info)

Idiopathic Thrombocytopenic Purpura (ITP) is a medical condition characterized by a low platelet count (thrombocytopenia) in the blood without an identifiable cause. Platelets are small blood cells that help your body form clots to stop bleeding. When you don't have enough platelets, you may bleed excessively or spontaneously, causing purpura, which refers to purple-colored spots on the skin that result from bleeding under the skin.

In ITP, the immune system mistakenly attacks and destroys platelets, leading to their decreased levels in the blood. This condition can occur at any age but is more common in children following a viral infection, and in adults after the age of 30-40 years. Symptoms may include easy or excessive bruising, prolonged bleeding from cuts, spontaneous bleeding from the gums or nose, blood blisters, and small red or purple spots on the skin (petechiae).

Depending on the severity of thrombocytopenia and the presence of bleeding symptoms, ITP treatment may include observation, corticosteroids, intravenous immunoglobulin (IVIG), or other medications that modify the immune system's response. In severe cases or when other treatments are ineffective, surgical removal of the spleen (splenectomy) might be considered.

Thrombotic thrombocytopenic purpura (TTP) is a rare but serious blood disorder. It's characterized by the formation of small blood clots throughout the body, which can lead to serious complications such as low platelet count (thrombocytopenia), hemolytic anemia, neurological symptoms, and kidney damage.

The term "purpura" refers to the purple-colored spots on the skin that result from bleeding under the skin. In TTP, these spots are caused by the rupture of red blood cells that have been damaged by the abnormal clotting process.

TTP is often caused by a deficiency or inhibitor of ADAMTS13, a protein in the blood that helps to regulate the formation of blood clots. This deficiency or inhibitor can lead to the formation of large clots called microthrombi, which can block small blood vessels throughout the body and cause tissue damage.

TTP is a medical emergency that requires prompt treatment with plasma exchange therapy, which involves removing and replacing the patient's plasma to restore normal levels of ADAMTS13 and prevent further clotting. Other treatments may include corticosteroids, immunosuppressive drugs, and rituximab.

Thrombocytopenic purpura (TTP) is a rare blood disorder characterized by the abnormal breakdown of platelets, leading to a low platelet count (thrombocytopenia). Platelets are small blood cells that help your body form clots to stop bleeding. A low platelet count can cause purple spots on the skin (purpura) and easy or excessive bruising or bleeding.

TTP is caused by the formation of blood clots in small blood vessels throughout the body, which can lead to serious complications such as damage to the heart, brain, and kidneys if left untreated. The condition can be acute (sudden onset) or chronic (long-term).

TTP is often caused by an autoimmune response where the body's immune system produces antibodies that attack and destroy a protein called ADAMTS13, which is necessary for breaking down large von Willebrand factor proteins in the blood. Without enough ADAMTS13, these proteins can form clots and deplete platelets, leading to thrombocytopenia and purpura.

Treatment typically involves plasma exchange therapy to replace the missing or nonfunctional ADAMTS13 protein and suppress the immune system's production of antibodies. Corticosteroids, immunosuppressive drugs, and rituximab may also be used in treatment.

Purpura is a medical term that refers to the appearance of purple-colored spots on the skin or mucous membranes, caused by bleeding underneath the skin due to various factors such as blood clotting disorders, vasculitis (inflammation of the blood vessels), severe thrombocytopenia (low platelet count), or use of certain medications. These spots can vary in size and shape, ranging from small pinpoint hemorrhages (petechiae) to larger, irregularly shaped patches (ecchymoses). The bleeding is usually not caused by trauma or injury to the area. It's important to consult a healthcare professional if you notice any unexplained purpuric spots on your skin or mucous membranes, as they can indicate an underlying medical condition that requires further evaluation and treatment.

Henoch-Schönlein purpura (HSP) is a type of small vessel vasculitis, which is a condition characterized by inflammation of the blood vessels. HSP primarily affects children, but it can occur in adults as well. It is named after two German physicians, Eduard Heinrich Henoch and Johann Schönlein, who first described the condition in the mid-19th century.

The main feature of HSP is a purpuric rash, which is a type of rash that appears as small, red or purple spots on the skin. The rash is caused by leakage of blood from the small blood vessels (capillaries) beneath the skin. In HSP, this rash typically occurs on the legs and buttocks, but it can also affect other parts of the body, such as the arms, face, and trunk.

In addition to the purpuric rash, HSP is often accompanied by other symptoms, such as joint pain and swelling, abdominal pain, nausea, vomiting, and diarrhea. In severe cases, it can also affect the kidneys, leading to hematuria (blood in the urine) and proteinuria (protein in the urine).

The exact cause of HSP is not known, but it is thought to be related to an abnormal immune response to certain triggers, such as infections or medications. Treatment typically involves supportive care, such as pain relief and fluid replacement, as well as medications to reduce inflammation and suppress the immune system. In most cases, HSP resolves on its own within a few weeks or months, but it can lead to serious complications in some individuals.

A platelet count is a laboratory test that measures the number of platelets, also known as thrombocytes, in a sample of blood. Platelets are small, colorless cell fragments that circulate in the blood and play a crucial role in blood clotting. They help to stop bleeding by sticking together to form a plug at the site of an injured blood vessel.

A normal platelet count ranges from 150,000 to 450,000 platelets per microliter (µL) of blood. A lower than normal platelet count is called thrombocytopenia, while a higher than normal platelet count is known as thrombocytosis.

Abnormal platelet counts can be a sign of various medical conditions, including bleeding disorders, infections, certain medications, and some types of cancer. It is important to consult with a healthcare provider if you have any concerns about your platelet count or if you experience symptoms such as easy bruising, prolonged bleeding, or excessive menstrual flow.

Plasma exchange, also known as plasmapheresis, is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies, clotting factors, or toxins, is then removed and replaced with fresh plasma or a plasma substitute. This process helps to remove the harmful substances from the blood and allows the body to replenish its own plasma with normal components. Plasma exchange is used in the treatment of various medical conditions including autoimmune diseases, poisonings, and certain types of kidney diseases.

A splenectomy is a surgical procedure in which the spleen is removed from the body. The spleen is an organ located in the upper left quadrant of the abdomen, near the stomach and behind the ribs. It plays several important roles in the body, including fighting certain types of infections, removing old or damaged red blood cells from the circulation, and storing platelets and white blood cells.

There are several reasons why a splenectomy may be necessary, including:

* Trauma to the spleen that cannot be repaired
* Certain types of cancer, such as Hodgkin's lymphoma or non-Hodgkin's lymphoma
* Sickle cell disease, which can cause the spleen to enlarge and become damaged
* A ruptured spleen, which can be life-threatening if not treated promptly
* Certain blood disorders, such as idiopathic thrombocytopenic purpura (ITP) or hemolytic anemia

A splenectomy is typically performed under general anesthesia and may be done using open surgery or laparoscopically. After the spleen is removed, the incision(s) are closed with sutures or staples. Recovery time varies depending on the individual and the type of surgery performed, but most people are able to return to their normal activities within a few weeks.

It's important to note that following a splenectomy, individuals may be at increased risk for certain types of infections, so it's recommended that they receive vaccinations to help protect against these infections. They should also seek medical attention promptly if they develop fever, chills, or other signs of infection.

Thrombocytopenia is a medical condition characterized by an abnormally low platelet count (thrombocytes) in the blood. Platelets are small cell fragments that play a crucial role in blood clotting, helping to stop bleeding when a blood vessel is damaged. A healthy adult typically has a platelet count between 150,000 and 450,000 platelets per microliter of blood. Thrombocytopenia is usually diagnosed when the platelet count falls below 150,000 platelets/µL.

Thrombocytopenia can be classified into three main categories based on its underlying cause:

1. Immune thrombocytopenia (ITP): An autoimmune disorder where the immune system mistakenly attacks and destroys its own platelets, leading to a decreased platelet count. ITP can be further divided into primary or secondary forms, depending on whether it occurs alone or as a result of another medical condition or medication.
2. Decreased production: Thrombocytopenia can occur when there is insufficient production of platelets in the bone marrow due to various causes, such as viral infections, chemotherapy, radiation therapy, leukemia, aplastic anemia, or vitamin B12 or folate deficiency.
3. Increased destruction or consumption: Thrombocytopenia can also result from increased platelet destruction or consumption due to conditions like disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or severe bacterial infections.

Symptoms of thrombocytopenia may include easy bruising, prolonged bleeding from cuts, spontaneous nosebleeds, bleeding gums, blood in urine or stools, and skin rashes like petechiae (small red or purple spots) or purpura (larger patches). The severity of symptoms can vary depending on the degree of thrombocytopenia and the presence of any underlying conditions. Treatment for thrombocytopenia depends on the cause and may include medications, transfusions, or addressing the underlying condition.

ADAM (A Disintegrin And Metalloprotease) proteins are a family of type I transmembrane proteins that contain several distinct domains, including a prodomain, a metalloprotease domain, a disintegrin-like domain, a cysteine-rich domain, a transmembrane domain, and a cytoplasmic tail. These proteins are involved in various biological processes such as cell adhesion, migration, proteolysis, and signal transduction.

ADAM proteins have been found to play important roles in many physiological and pathological conditions, including fertilization, neurodevelopment, inflammation, and cancer metastasis. For example, ADAM12 is involved in the fusion of myoblasts during muscle development, while ADAM17 (also known as TACE) plays a crucial role in the shedding of membrane-bound proteins such as tumor necrosis factor-alpha and epidermal growth factor receptor ligands.

Abnormalities in ADAM protein function have been implicated in various diseases, including cancer, Alzheimer's disease, and arthritis. Therefore, understanding the structure and function of these proteins has important implications for the development of novel therapeutic strategies.

Purpura fulminans is a severe, life-threatening condition characterized by the rapid progression of hemorrhagic purpura (discoloration of the skin due to bleeding under the skin) and disseminated intravascular coagulation (DIC), leading to thrombosis and necrosis of the skin and underlying tissues. It can be classified into two types: acute infectious purpura fulminans, which is caused by bacterial infections such as meningococcus or pneumococcus; and chronic purpura fulminans, which is associated with autoimmune disorders or protein C or S deficiencies. The condition can lead to serious complications such as sepsis, organ failure, and death if not promptly diagnosed and treated.

Blood platelets, also known as thrombocytes, are small, colorless cell fragments in our blood that play an essential role in normal blood clotting. They are formed in the bone marrow from large cells called megakaryocytes and circulate in the blood in an inactive state until they are needed to help stop bleeding. When a blood vessel is damaged, platelets become activated and change shape, releasing chemicals that attract more platelets to the site of injury. These activated platelets then stick together to form a plug, or clot, that seals the wound and prevents further blood loss. In addition to their role in clotting, platelets also help to promote healing by releasing growth factors that stimulate the growth of new tissue.

A platelet transfusion is the process of medically administering platelets, which are small blood cells that help your body form clots to stop bleeding. Platelet transfusions are often given to patients with low platelet counts or dysfunctional platelets due to various reasons such as chemotherapy, bone marrow transplantation, disseminated intravascular coagulation (DIC), and other medical conditions leading to increased consumption or destruction of platelets. This procedure helps to prevent or treat bleeding complications in these patients. It's important to note that platelet transfusions should be given under the supervision of a healthcare professional, taking into account the patient's clinical condition, platelet count, and potential risks associated with transfusion reactions.

Hemolytic-Uremic Syndrome (HUS) is a serious condition that affects the blood and kidneys. It is characterized by three major features: the breakdown of red blood cells (hemolysis), the abnormal clotting of small blood vessels (microthrombosis), and acute kidney failure.

The breakdown of red blood cells leads to the release of hemoglobin into the bloodstream, which can cause anemia. The microthrombi can obstruct the flow of blood in the kidneys' filtering system (glomeruli), leading to damaged kidney function and potentially acute kidney failure.

HUS is often caused by a bacterial infection, most commonly Escherichia coli (E. coli) that produces Shiga toxins. This form of HUS is known as STEC-HUS or Stx-HUS. Other causes include infections with other bacteria, viruses, medications, pregnancy complications, and certain medical conditions such as autoimmune diseases.

Symptoms of HUS may include fever, fatigue, decreased urine output, blood in the stool, swelling in the face, hands, or feet, and irritability or confusion. Treatment typically involves supportive care, including dialysis for kidney failure, transfusions to replace lost red blood cells, and managing high blood pressure. In severe cases, a kidney transplant may be necessary.

Intravenous Immunoglobulins (IVIG) are a preparation of antibodies, specifically immunoglobulins, that are derived from the plasma of healthy donors. They are administered intravenously to provide passive immunity and help boost the immune system's response in individuals with weakened or compromised immune systems. IVIG can be used for various medical conditions such as primary immunodeficiency disorders, secondary immunodeficiencies, autoimmune diseases, and some infectious diseases. The administration of IVIG can help prevent infections, reduce the severity and frequency of infections, and manage the symptoms of certain autoimmune disorders. It is important to note that while IVIG provides temporary immunity, it does not replace a person's own immune system.

Danazol is a synthetic, orally active androgenic steroid with antigonadotropic properties. It is used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol works by suppressing the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, which in turn inhibits the growth of ovarian tissue and reduces the production of estrogen and progesterone. This leads to a decrease in the symptoms associated with endometriosis and fibrocystic breast disease. In the case of hereditary angioedema, danazol helps prevent attacks by increasing the levels of a protein called C1 esterase inhibitor, which is necessary for regulating the immune system and preventing inflammation.

The common side effects of danazol include weight gain, acne, oily skin, increased hair growth, changes in menstrual cycle, decreased breast size, deepening of the voice, and emotional lability. Rare but serious side effects may include liver damage, blood clots, and adrenal gland problems. Danazol is contraindicated in pregnancy due to its potential virilizing effects on the fetus. It should be used with caution in individuals with a history of liver disease, heart disease, or seizure disorders.

The medical definition of danazol can be summarized as follows:

Danazol (dan-a-zole)

A synthetic androgenic steroid with antigonadotropic properties, used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol suppresses the release of FSH and LH from the pituitary gland, inhibiting ovarian tissue growth and reducing estrogen and progesterone production. In hereditary angioedema, danazol increases C1 esterase inhibitor levels to prevent attacks. Common side effects include weight gain, acne, increased hair growth, menstrual changes, decreased breast size, deepened voice, and emotional lability. Rare but serious side effects may involve liver damage, blood clots, or adrenal gland problems. Danazol is contraindicated in pregnancy due to potential virilizing effects on the fetus and should be used with caution in individuals with a history of liver disease, heart disease, or seizure disorders.

Plasmapheresis is a medical procedure where the liquid portion of the blood (plasma) is separated from the blood cells. The plasma, which may contain harmful substances such as antibodies or toxins, is then removed and replaced with fresh plasma or a plasma substitute. The remaining blood cells are mixed with the new plasma and returned to the body. This process is also known as therapeutic plasma exchange (TPE). It's used to treat various medical conditions including certain autoimmune diseases, poisonings, and neurological disorders.

Hematologic pregnancy complications refer to disorders related to the blood and blood-forming tissues that occur during pregnancy. These complications can have serious consequences for both the mother and the fetus if not properly managed. Some common hematologic pregnancy complications include:

1. Anemia: A condition characterized by a decrease in the number of red blood cells or hemoglobin in the blood, which can lead to fatigue, weakness, and shortness of breath. Iron-deficiency anemia is the most common type of anemia during pregnancy.
2. Thrombocytopenia: A condition characterized by a decrease in the number of platelets (cells that help blood clot) in the blood. Mild thrombocytopenia is relatively common during pregnancy, but severe thrombocytopenia can increase the risk of bleeding during delivery.
3. Gestational thrombotic thrombocytopenic purpura (GTTP): A rare but serious disorder that can cause blood clots to form in small blood vessels throughout the body, leading to a decrease in the number of platelets and red blood cells. GTTP can cause serious complications such as stroke, kidney failure, and even death if not promptly diagnosed and treated.
4. Disseminated intravascular coagulation (DIC): A condition characterized by abnormal clotting and bleeding throughout the body. DIC can be triggered by various conditions such as severe infections, pregnancy complications, or cancer.
5. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: A serious complication of pregnancy that can cause damage to the liver and lead to bleeding. HELLP syndrome is often associated with preeclampsia, a condition characterized by high blood pressure and damage to organs such as the liver and kidneys.

It's important for pregnant women to receive regular prenatal care to monitor for these and other potential complications, and to seek prompt medical attention if any concerning symptoms arise.

Ecchymosis is a medical term that refers to a discoloration of the skin caused by the leakage of blood from ruptured blood vessels into the tissues beneath. It is typically caused by trauma or injury to the affected area, which results in the escape of blood from the damaged blood vessels. The escaped blood collects under the skin, causing a bruise or a purple, blue, or blackish patch on the skin's surface.

Ecchymosis can occur anywhere on the body and can vary in size and shape depending on the extent of the injury. While ecchymosis is generally harmless and resolves on its own within a few days to a week, it can be a sign of an underlying medical condition, such as a bleeding disorder or a blood vessel abnormality. In these cases, further evaluation and treatment may be necessary.

Human platelet antigens (HPAs) are a group of cell surface proteins found on platelets and megakaryocytes, which are the precursor cells that produce platelets. These antigens can stimulate an immune response when they are recognized as foreign by the body's immune system, leading to the production of antibodies against them.

HPAs are classified into several different systems based on their genetic inheritance and immunological properties. The most well-known HPA systems are HPA-1, HPA-2, HPA-3, HPA-4, and HPA-5. Each system consists of a pair of alleles, one inherited from each parent, that code for different variants of the antigen.

HPAs can play a role in the development of certain bleeding disorders, such as neonatal alloimmune thrombocytopenia (NAIT) and post-transfusion purpura (PTP). NAIT occurs when a pregnant woman develops antibodies against her fetus's HPAs, leading to low platelet counts and bleeding in the newborn. PTP can occur after a transfusion of blood products containing HPAs that are not compatible with the recipient's HPAs, leading to an immune response and destruction of the transfused platelets.

It is important for healthcare providers to consider HPA compatibility when performing platelet transfusions or managing pregnant women at risk of developing antibodies against HPAs.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

Thrombopoietin (TPO) is a glycoprotein hormone that plays a crucial role in the regulation of platelet production, also known as thrombopoiesis. It is primarily produced by the liver and to some extent by megakaryocytes, which are the cells responsible for producing platelets.

TPO binds to its receptor, c-Mpl, on the surface of megakaryocytes and their precursor cells, stimulating their proliferation, differentiation, and maturation into platelets. By regulating the number of platelets in circulation, TPO helps maintain hemostasis, the process that prevents excessive bleeding after injury.

In addition to its role in thrombopoiesis, TPO has been shown to have potential effects on other cell types, including hematopoietic stem cells and certain immune cells. However, its primary function remains the regulation of platelet production.

Von Willebrand factor (vWF) is a large multimeric glycoprotein that plays a crucial role in hemostasis, the process which leads to the cessation of bleeding and the formation of a blood clot. It was named after Erik Adolf von Willebrand, a Finnish physician who first described the disorder associated with its deficiency, known as von Willebrand disease (vWD).

The primary functions of vWF include:

1. Platelet adhesion and aggregation: vWF mediates the initial attachment of platelets to damaged blood vessel walls by binding to exposed collagen fibers and then interacting with glycoprotein Ib (GPIb) receptors on the surface of platelets, facilitating platelet adhesion. Subsequently, vWF also promotes platelet-platelet interactions (aggregation) through its interaction with platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptors under high shear stress conditions found in areas of turbulent blood flow, such as arterioles and the capillary bed.

2. Transport and stabilization of coagulation factor VIII: vWF serves as a carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation and maintaining its stability in circulation. This interaction between vWF and FVIII is essential for the proper functioning of the coagulation cascade, particularly in the context of vWD, where impaired FVIII function can lead to bleeding disorders.

3. Wound healing: vWF contributes to wound healing by promoting platelet adhesion and aggregation at the site of injury, which facilitates the formation of a provisional fibrin-based clot that serves as a scaffold for tissue repair and regeneration.

In summary, von Willebrand factor is a vital hemostatic protein involved in platelet adhesion, aggregation, coagulation factor VIII stabilization, and wound healing. Deficiencies or dysfunctions in vWF can lead to bleeding disorders such as von Willebrand disease.

Idiopathic Pulmonary Fibrosis (IPF) is a specific type of chronic, progressive, and irreversible fibrotic lung disease of unknown cause, characterized by scarring (fibrosis) in the lungs that thickens and stiffens the lining of the air sacs (alveoli). This makes it increasingly difficult for the lungs to transfer oxygen into the bloodstream, leading to shortness of breath, cough, decreased exercise tolerance, and, eventually, respiratory failure.

The term "idiopathic" means that the cause of the disease is unknown. The diagnosis of IPF requires a combination of clinical, radiological, and pathological findings, excluding other known causes of pulmonary fibrosis. It primarily affects middle-aged to older adults, with a higher prevalence in men than women.

The progression of IPF varies from person to person, but the prognosis is generally poor, with a median survival time of 3-5 years after diagnosis. Currently, there are two FDA-approved medications for the treatment of IPF (nintedanib and pirfenidone), which can help slow down disease progression but do not cure the condition. Lung transplantation remains an option for select patients with advanced IPF.

Hyperglobulinemic purpura is a medical condition characterized by the presence of purple-colored spots on the skin (purpura) due to bleeding under the skin caused by an abnormal increase in certain types of proteins called globulins in the blood. This condition is often associated with various underlying diseases, such as autoimmune disorders, infections, or cancer, that can lead to excessive production of these proteins.

The increased levels of globulins can cause damage to the walls of small blood vessels (capillaries), leading to leakage of red blood cells and plasma into the surrounding tissues. This results in the characteristic purpuric lesions on the skin, which may vary in size and distribution. In addition to skin manifestations, hyperglobulinemic purpura can also affect other organs, such as the kidneys, leading to further complications.

It is important to note that hyperglobulinemic purpura is a relatively rare condition, and its diagnosis typically requires a thorough evaluation of the patient's medical history, physical examination, laboratory tests, and imaging studies to identify the underlying cause and determine appropriate treatment.

I'm sorry for any confusion, but "Oklahoma" is not a medical term or condition. It is a state in the south central region of the United States. If you have any questions about medical terminology or health-related topics, I would be happy to try and help answer them!

Megakaryocytes are large, specialized bone marrow cells that are responsible for the production and release of platelets (also known as thrombocytes) into the bloodstream. Platelets play an essential role in blood clotting and hemostasis, helping to prevent excessive bleeding during injuries or trauma.

Megakaryocytes have a unique structure with multilobed nuclei and abundant cytoplasm rich in organelles called alpha-granules and dense granules, which store various proteins, growth factors, and enzymes necessary for platelet function. As megakaryocytes mature, they extend long cytoplasmic processes called proplatelets into the bone marrow sinuses, where these extensions fragment into individual platelets that are released into circulation.

Abnormalities in megakaryocyte number, size, or function can lead to various hematological disorders, such as thrombocytopenia (low platelet count), thrombocytosis (high platelet count), and certain types of leukemia.

Thrombopoiesis is the process of formation and development of thrombocytes or platelets, which are small, colorless cell fragments in our blood that play an essential role in clotting. Thrombopoiesis occurs inside the bone marrow, where stem cells differentiate into megakaryoblasts, then progressively develop into promegakaryocytes and megakaryocytes. These megakaryocytes subsequently undergo a process called cytoplasmic fragmentation to produce platelets.

The regulation of thrombopoiesis is primarily controlled by the hormone thrombopoietin (TPO), which is produced mainly in the liver and binds to the thrombopoietin receptor (c-Mpl) on megakaryocytes and their precursors. This binding stimulates the proliferation, differentiation, and maturation of megakaryocytes, leading to an increase in platelet production.

Abnormalities in thrombopoiesis can result in conditions such as thrombocytopenia (low platelet count) or thrombocytosis (high platelet count), which may be associated with bleeding disorders or increased risk of thrombosis, respectively.

Metalloendopeptidases are a type of enzymes that cleave peptide bonds in proteins, specifically at interior positions within the polypeptide chain. They require metal ions as cofactors for their catalytic activity, typically zinc (Zn2+) or cobalt (Co2+). These enzymes play important roles in various biological processes such as protein degradation, processing, and signaling. Examples of metalloendopeptidases include thermolysin, matrix metalloproteinases (MMPs), and neutrophil elastase.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Hemolytic anemia, autoimmune is a type of anemia characterized by the premature destruction of red blood cells (RBCs) in which the immune system mistakenly attacks and destroys its own RBCs. This occurs when the body produces autoantibodies that bind to the surface of RBCs, leading to their rupture (hemolysis). The symptoms may include fatigue, weakness, shortness of breath, and dark colored urine. The diagnosis is made through blood tests that measure the number and size of RBCs, reticulocyte count, and the presence of autoantibodies. Treatment typically involves suppressing the immune system with medications such as corticosteroids or immunosuppressive drugs, and sometimes removal of the spleen (splenectomy) may be necessary.

Thrombopoietin receptors are a type of cell surface receptor found on megakaryocytes and platelets. They are also known as MPL (myeloproliferative leukemia virus) receptors. Thrombopoietin is a hormone that regulates the production of platelets in the body, and it binds to these receptors to stimulate the proliferation and differentiation of megakaryocytes, which are large bone marrow cells that produce platelets.

The thrombopoietin receptor is a type I transmembrane protein with an extracellular domain that contains the thrombopoietin-binding site, a single transmembrane domain, and an intracellular domain that contains several tyrosine residues that become phosphorylated upon thrombopoietin binding. This triggers a signaling cascade that leads to the activation of various downstream pathways involved in cell proliferation, differentiation, and survival.

Mutations in the thrombopoietin receptor gene have been associated with certain myeloproliferative neoplasms, such as essential thrombocythemia and primary myelofibrosis, which are characterized by excessive platelet production and bone marrow fibrosis.

Thrombotic microangiopathies (TMAs) are a group of disorders characterized by the formation of blood clots in small blood vessels, causing damage to the end organs. This process leads to a constellation of clinical symptoms including thrombocytopenia (low platelet count), microangiopathic hemolytic anemia (breakdown of red blood cells leading to anemia), and organ dysfunction such as renal failure, neurological impairment, or cardiac involvement.

TMAs can be primary or secondary. Primary TMAs are caused by genetic mutations affecting the complement system, coagulation cascade, or other regulatory proteins involved in vascular homeostasis. Examples of primary TMAs include atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and complement-mediated TMA.

Secondary TMAs are caused by various underlying conditions or exposures, such as infections, autoimmune diseases, malignancies, drugs, pregnancy-related complications, or other systemic disorders. The pathogenesis of secondary TMAs is often multifactorial and may involve endothelial injury, complement activation, and platelet aggregation.

The diagnosis of TMAs requires a combination of clinical, laboratory, and sometimes histopathological findings. Treatment depends on the underlying cause and may include supportive care, plasma exchange, immunosuppressive therapy, or targeted therapies such as complement inhibitors.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

Hemolytic anemia is a type of anemia that occurs when red blood cells are destroyed (hemolysis) faster than they can be produced. Red blood cells are essential for carrying oxygen throughout the body. When they are destroyed, hemoglobin and other cellular components are released into the bloodstream, which can lead to complications such as kidney damage and gallstones.

Hemolytic anemia can be inherited or acquired. Inherited forms of the condition may result from genetic defects that affect the structure or function of red blood cells. Acquired forms of hemolytic anemia can be caused by various factors, including infections, medications, autoimmune disorders, and certain medical conditions such as cancer or blood disorders.

Symptoms of hemolytic anemia may include fatigue, weakness, shortness of breath, pale skin, jaundice (yellowing of the skin and eyes), dark urine, and a rapid heartbeat. Treatment for hemolytic anemia depends on the underlying cause and may include medications, blood transfusions, or surgery.

Platelet membrane glycoproteins are specialized proteins found on the surface of platelets, which are small blood cells responsible for clotting. These glycoproteins play crucial roles in various processes related to hemostasis and thrombosis, including platelet adhesion, activation, and aggregation.

There are several key platelet membrane glycoproteins, such as:

1. Glycoprotein (GP) Ia/IIa (also known as integrin α2β1): This glycoprotein mediates the binding of platelets to collagen fibers in the extracellular matrix, facilitating platelet adhesion and activation.
2. GP IIb/IIIa (also known as integrin αIIbβ3): This is the most abundant glycoprotein on the platelet surface and functions as a receptor for fibrinogen, von Willebrand factor, and other adhesive proteins. Upon activation, GP IIb/IIIa undergoes conformational changes that enable it to bind these ligands, leading to platelet aggregation and clot formation.
3. GPIb-IX-V: This glycoprotein complex is involved in the initial tethering and adhesion of platelets to von Willebrand factor (vWF) in damaged blood vessels. It consists of four subunits: GPIbα, GPIbβ, GPIX, and GPV.
4. GPVI: This glycoprotein is essential for platelet activation upon contact with collagen. It associates with the Fc receptor γ-chain (FcRγ) to form a signaling complex that triggers intracellular signaling pathways, leading to platelet activation and aggregation.

Abnormalities in these platelet membrane glycoproteins can lead to bleeding disorders or thrombotic conditions. For example, mutations in GPIIb/IIIa can result in Glanzmann's thrombasthenia, a severe bleeding disorder characterized by impaired platelet aggregation. On the other hand, increased expression or activation of these glycoproteins may contribute to the development of arterial thrombosis and cardiovascular diseases.

The adrenal cortex hormones are a group of steroid hormones produced and released by the outer portion (cortex) of the adrenal glands, which are located on top of each kidney. These hormones play crucial roles in regulating various physiological processes, including:

1. Glucose metabolism: Cortisol helps control blood sugar levels by increasing glucose production in the liver and reducing its uptake in peripheral tissues.
2. Protein and fat metabolism: Cortisol promotes protein breakdown and fatty acid mobilization, providing essential building blocks for energy production during stressful situations.
3. Immune response regulation: Cortisol suppresses immune function to prevent overactivation and potential damage to the body during stress.
4. Cardiovascular function: Aldosterone regulates electrolyte balance and blood pressure by promoting sodium reabsorption and potassium excretion in the kidneys.
5. Sex hormone production: The adrenal cortex produces small amounts of sex hormones, such as androgens and estrogens, which contribute to sexual development and function.
6. Growth and development: Cortisol plays a role in normal growth and development by influencing the activity of growth-promoting hormones like insulin-like growth factor 1 (IGF-1).

The main adrenal cortex hormones include:

1. Glucocorticoids: Cortisol is the primary glucocorticoid, responsible for regulating metabolism and stress response.
2. Mineralocorticoids: Aldosterone is the primary mineralocorticoid, involved in electrolyte balance and blood pressure regulation.
3. Androgens: Dehydroepiandrosterone (DHEA) and its sulfate derivative (DHEAS) are the most abundant adrenal androgens, contributing to sexual development and function.
4. Estrogens: Small amounts of estrogens are produced by the adrenal cortex, mainly in women.

Disorders related to impaired adrenal cortex hormone production or regulation can lead to various clinical manifestations, such as Addison's disease (adrenal insufficiency), Cushing's syndrome (hypercortisolism), and congenital adrenal hyperplasia (CAH).

A chronic disease is a long-term medical condition that often progresses slowly over a period of years and requires ongoing management and care. These diseases are typically not fully curable, but symptoms can be managed to improve quality of life. Common chronic diseases include heart disease, stroke, cancer, diabetes, arthritis, and COPD (chronic obstructive pulmonary disease). They are often associated with advanced age, although they can also affect children and younger adults. Chronic diseases can have significant impacts on individuals' physical, emotional, and social well-being, as well as on healthcare systems and society at large.

Prednisolone is a synthetic glucocorticoid drug, which is a class of steroid hormones. It is commonly used in the treatment of various inflammatory and autoimmune conditions due to its potent anti-inflammatory and immunosuppressive effects. Prednisolone works by binding to specific receptors in cells, leading to changes in gene expression that reduce the production of substances involved in inflammation, such as cytokines and prostaglandins.

Prednisolone is available in various forms, including tablets, syrups, and injectable solutions. It can be used to treat a wide range of medical conditions, including asthma, rheumatoid arthritis, inflammatory bowel disease, allergies, skin conditions, and certain types of cancer.

Like other steroid medications, prednisolone can have significant side effects if used in high doses or for long periods of time. These may include weight gain, mood changes, increased risk of infections, osteoporosis, diabetes, and adrenal suppression. As a result, the use of prednisolone should be closely monitored by a healthcare professional to ensure that its benefits outweigh its risks.

Scoliosis is a medical condition characterized by an abnormal lateral curvature of the spine, which most often occurs in the thoracic or lumbar regions. The curvature can be "C" or "S" shaped and may also include rotation of the vertebrae. Mild scoliosis doesn't typically cause problems, but severe cases can interfere with breathing and other bodily functions.

The exact cause of most scoliosis is unknown, but it may be related to genetic factors. It often develops in the pre-teen or teenage years, particularly in girls, and is more commonly found in individuals with certain neuromuscular disorders such as cerebral palsy and muscular dystrophy.

Treatment for scoliosis depends on the severity of the curve, its location, and the age and expected growth of the individual. Mild cases may only require regular monitoring to ensure the curve doesn't worsen. More severe cases may require bracing or surgery to correct the curvature and prevent it from getting worse.

Immunologic factors refer to the elements of the immune system that contribute to the body's defense against foreign substances, infectious agents, and cancerous cells. These factors include various types of white blood cells (such as lymphocytes, neutrophils, monocytes, and eosinophils), antibodies, complement proteins, cytokines, and other molecules involved in the immune response.

Immunologic factors can be categorized into two main types: innate immunity and adaptive immunity. Innate immunity is the non-specific defense mechanism that provides immediate protection against pathogens through physical barriers (e.g., skin, mucous membranes), chemical barriers (e.g., stomach acid, enzymes), and inflammatory responses. Adaptive immunity, on the other hand, is a specific defense mechanism that develops over time as the immune system learns to recognize and respond to particular pathogens or antigens.

Abnormalities in immunologic factors can lead to various medical conditions, such as autoimmune disorders, immunodeficiency diseases, and allergies. Therefore, understanding immunologic factors is crucial for diagnosing and treating these conditions.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Hemorrhage is defined in the medical context as an excessive loss of blood from the circulatory system, which can occur due to various reasons such as injury, surgery, or underlying health conditions that affect blood clotting or the integrity of blood vessels. The bleeding may be internal, external, visible, or concealed, and it can vary in severity from minor to life-threatening, depending on the location and extent of the bleeding. Hemorrhage is a serious medical emergency that requires immediate attention and treatment to prevent further blood loss, organ damage, and potential death.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Juvenile arthritis (JA) is a term used to describe a group of autoimmune and inflammatory disorders that can affect children aged 16 or younger. In JA, the immune system mistakenly attacks the body's own tissues, causing inflammation in the joints, which can lead to pain, swelling, stiffness, and damage over time.

There are several types of juvenile arthritis, including:

1. Juvenile Idiopathic Arthritis (JIA): This is the most common form of JA, and it includes several subtypes that are classified based on the number of joints affected and the presence or absence of certain symptoms.
2. Juvenile Systemic Lupus Erythematosus (JSLE): This is a type of lupus that affects children, and it can cause inflammation in various parts of the body, including the joints, skin, kidneys, and lungs.
3. Juvenile Dermatomyositis (JDM): This is a rare autoimmune disorder that causes inflammation of the blood vessels, leading to muscle weakness, skin rashes, and joint pain.
4. Juvenile Scleroderma: This is a group of disorders that cause hardening and tightening of the skin and connective tissues, which can also affect the joints.
5. Juvenile Psoriatic Arthritis (JPsA): This is a type of arthritis that affects children who have psoriasis, a chronic skin condition. JPsA can cause inflammation in the joints and skin.

The causes of juvenile arthritis are not fully understood, but it is believed to involve a combination of genetic and environmental factors. There is no cure for JA, but treatments such as medication, physical therapy, and lifestyle changes can help manage the symptoms and prevent long-term complications.

Disseminated Intravascular Coagulation (DIC) is a complex medical condition characterized by the abnormal activation of the coagulation cascade, leading to the formation of blood clots in small blood vessels throughout the body. This process can result in the consumption of clotting factors and platelets, which can then lead to bleeding complications. DIC can be caused by a variety of underlying conditions, including sepsis, trauma, cancer, and obstetric emergencies.

The term "disseminated" refers to the widespread nature of the clotting activation, while "intravascular" indicates that the clotting is occurring within the blood vessels. The condition can manifest as both bleeding and clotting complications, which can make it challenging to diagnose and manage.

The diagnosis of DIC typically involves laboratory tests that evaluate coagulation factors, platelet count, fibrin degradation products, and other markers of coagulation activation. Treatment is focused on addressing the underlying cause of the condition while also managing any bleeding or clotting complications that may arise.

Isoantibodies are antibodies produced by the immune system that recognize and react to antigens (markers) found on the cells or tissues of another individual of the same species. These antigens are typically proteins or carbohydrates present on the surface of red blood cells, but they can also be found on other cell types.

Isoantibodies are formed when an individual is exposed to foreign antigens, usually through blood transfusions, pregnancy, or tissue transplantation. The exposure triggers the immune system to produce specific antibodies against these antigens, which can cause a harmful immune response if the individual receives another transfusion or transplant from the same donor in the future.

There are two main types of isoantibodies:

1. Agglutinins: These are IgM antibodies that cause red blood cells to clump together (agglutinate) when mixed with the corresponding antigen. They develop rapidly after exposure and can cause immediate transfusion reactions or hemolytic disease of the newborn in pregnant women.
2. Hemolysins: These are IgG antibodies that destroy red blood cells by causing their membranes to become more permeable, leading to lysis (bursting) of the cells and release of hemoglobin into the plasma. They take longer to develop but can cause delayed transfusion reactions or hemolytic disease of the newborn in pregnant women.

Isoantibodies are detected through blood tests, such as the crossmatch test, which determines compatibility between a donor's and recipient's blood before transfusions or transplants.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Hematology is a branch of medicine that deals with the study of blood, its physiology, and pathophysiology. It involves the diagnosis, treatment, and prevention of diseases related to the blood and blood-forming organs such as the bone marrow, spleen, and lymphatic system. This includes disorders of red and white blood cells, platelets, hemoglobin, blood vessels, and coagulation (blood clotting). Some common hematological diseases include anemia, leukemia, lymphoma, sickle cell disease, and bleeding disorders like hemophilia.

In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.

Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.

Thrombocytosis is a medical condition characterized by an abnormally high platelet count (also known as thrombocytes) in the blood. Platelets are small cell fragments that play a crucial role in blood clotting. A normal platelet count ranges from 150,000 to 450,000 platelets per microliter of blood. Thrombocytosis is typically defined as a platelet count exceeding 450,000-500,000 platelets/µL.

Thrombocytosis can be classified into two types: reactive (or secondary) thrombocytosis and primary (or essential) thrombocytosis. Reactive thrombocytosis is more common and occurs as a response to an underlying condition, such as infection, inflammation, surgery, or certain types of cancer. Primary thrombocytosis, on the other hand, is caused by intrinsic abnormalities in the bone marrow cells responsible for platelet production (megakaryocytes), and it is often associated with myeloproliferative neoplasms like essential thrombocythemia.

While mild thrombocytosis may not cause any symptoms, higher platelet counts can increase the risk of blood clots (thrombosis) and bleeding disorders due to excessive platelet aggregation. Symptoms of thrombocytosis may include headaches, dizziness, visual disturbances, or chest pain if a blood clot forms in the brain or heart. Bleeding symptoms can manifest as easy bruising, nosebleeds, or gastrointestinal bleeding.

Treatment for thrombocytosis depends on the underlying cause and the severity of the condition. In cases of reactive thrombocytosis, treating the underlying disorder often resolves the high platelet count. For primary thrombocytosis, medications like aspirin or cytoreductive therapy (such as hydroxyurea) may be used to reduce the risk of blood clots and control platelet production. Regular monitoring of platelet counts is essential for managing this condition and preventing potential complications.

Methylprednisolone is a synthetic glucocorticoid drug, which is a class of hormones that naturally occur in the body and are produced by the adrenal gland. It is often used to treat various medical conditions such as inflammation, allergies, and autoimmune disorders. Methylprednisolone works by reducing the activity of the immune system, which helps to reduce symptoms such as swelling, pain, and redness.

Methylprednisolone is available in several forms, including tablets, oral suspension, and injectable solutions. It may be used for short-term or long-term treatment, depending on the condition being treated. Common side effects of methylprednisolone include increased appetite, weight gain, insomnia, mood changes, and increased susceptibility to infections. Long-term use of methylprednisolone can lead to more serious side effects such as osteoporosis, cataracts, and adrenal suppression.

It is important to note that methylprednisolone should be used under the close supervision of a healthcare provider, as it can cause serious side effects if not used properly. The dosage and duration of treatment will depend on various factors such as the patient's age, weight, medical history, and the condition being treated.

Hemoglobinuria is a medical condition characterized by the presence of hemoglobin in the urine. Hemoglobin is a protein found in red blood cells that carries oxygen throughout the body. Normally, when red blood cells die, they are broken down and their hemoglobin is recycled. However, in certain conditions such as intravascular hemolysis (the destruction of red blood cells inside blood vessels), hemoglobin can be released into the bloodstream and then filtered by the kidneys into the urine.

Hemoglobinuria can be a symptom of various underlying medical conditions, including hemolytic anemias, disseminated intravascular coagulation (DIC), severe infections, snake bites, and exposure to certain toxins or medications. It is important to identify the underlying cause of hemoglobinuria, as treatment will depend on the specific condition.

In some cases, hemoglobinuria can lead to kidney damage due to the toxic effects of free hemoglobin on the renal tubules. This can result in acute or chronic kidney injury, and in severe cases, it may require dialysis or transplantation.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Phenazopyridine is a medication that functions as a urinary analgesic, which means it helps to relieve pain, burning, and discomfort in the urinary tract. It works by numbing the lining of the urinary tract, reducing the sensation of pain upon urination. Phenazopyridine is typically available in oral form, and its use is generally limited to short-term treatment (up to 2 days) of symptoms associated with urinary tract infections.

It is important to note that phenazopyridine does not treat the underlying infection; it only helps alleviate the discomfort caused by the infection. Antibiotics are necessary to address the infection itself. Moreover, phenazopyridine can cause side effects such as headache, dizziness, and stomach upset. It may also stain urine, sweat, and tears a reddish-orange color, which is harmless but can be alarming if not anticipated. Always consult with a healthcare professional for appropriate medical advice and treatment.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

A blood transfusion is a medical procedure in which blood or its components are transferred from one individual (donor) to another (recipient) through a vein. The donated blood can be fresh whole blood, packed red blood cells, platelets, plasma, or cryoprecipitate, depending on the recipient's needs. Blood transfusions are performed to replace lost blood due to severe bleeding, treat anemia, support patients undergoing major surgeries, or manage various medical conditions such as hemophilia, thalassemia, and leukemia. The donated blood must be carefully cross-matched with the recipient's blood type to minimize the risk of transfusion reactions.

The platelet glycoprotein GPIb-IX complex is a crucial receptor on the surface of platelets that plays a vital role in hemostasis and thrombosis. It is a heterotetrameric transmembrane protein complex composed of two disulfide-linked glycoprotein subunits, GPIbα, GPIbβ, GPV (Glycoprotein V), and GPIX (Glycoprotein IX).

The GPIb-IX complex is responsible for the initial interaction between platelets and von Willebrand factor (vWF) in the circulation. When blood vessels are damaged, exposed collagen recruits vWF to the site of injury, where it binds to the GPIbα subunit of the GPIb-IX complex, leading to platelet adhesion and activation. This interaction is critical for primary hemostasis, which helps prevent excessive blood loss from injured vessels.

Genetic mutations or deficiencies in the genes encoding these glycoproteins can lead to bleeding disorders such as Bernard-Soulier syndrome, a rare autosomal recessive disorder characterized by thrombocytopenia and large platelets with impaired vWF binding and platelet adhesion.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

Splenic tuberculosis is a form of extrapulmonary tuberculosis (ETB), which refers to a manifestation of the disease outside of the lungs. It is caused by the bacterium Mycobacterium tuberculosis.

In splenic tuberculosis, the infection involves the spleen (an organ located in the upper left part of the abdomen that filters blood and helps fight infection). The infection can occur through the hematogenous spread (dissemination via the bloodstream) from a primary focus elsewhere in the body, such as the lungs.

The disease presents with various symptoms, including fever, fatigue, weight loss, abdominal pain, and splenomegaly (enlargement of the spleen). Diagnosis often requires a combination of clinical evaluation, imaging studies, and microbiological or histopathological confirmation. Treatment typically involves a prolonged course of multidrug antibiotics to eliminate the infection and prevent complications.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Epistaxis is the medical term for nosebleed. It refers to the bleeding from the nostrils or nasal cavity, which can be caused by various factors such as dryness, trauma, inflammation, high blood pressure, or use of blood-thinning medications. Nosebleeds can range from minor nuisances to potentially life-threatening emergencies, depending on the severity and underlying cause. If you are experiencing a nosebleed that does not stop after 20 minutes of applying direct pressure, or if you are coughing up or vomiting blood, seek medical attention immediately.

Pancytopenia is a medical condition characterized by a reduction in the number of all three types of blood cells in the peripheral blood: red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). This condition can be caused by various underlying diseases, including bone marrow disorders, viral infections, exposure to toxic substances or radiation, vitamin deficiencies, and certain medications. Symptoms of pancytopenia may include fatigue, weakness, increased susceptibility to infections, and easy bruising or bleeding.

Gingival hemorrhage is the medical term for bleeding of the gingiva, or gums. It refers to the condition where the gums bleed, often as a result of trauma or injury, but also can be caused by various systemic conditions such as disorders of coagulation, leukemia, or scurvy.

Gingival hemorrhage is commonly seen in individuals with poor oral hygiene and periodontal disease, which can cause inflammation and damage to the gums. This can lead to increased susceptibility to bleeding, even during routine activities such as brushing or flossing. It's important to address any underlying causes of gingival hemorrhage to prevent further complications.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that can affect almost any organ or system in the body. In SLE, the immune system produces an exaggerated response, leading to the production of autoantibodies that attack the body's own cells and tissues, causing inflammation and damage. The symptoms and severity of SLE can vary widely from person to person, but common features include fatigue, joint pain, skin rashes (particularly a "butterfly" rash across the nose and cheeks), fever, hair loss, and sensitivity to sunlight.

Systemic lupus erythematosus can also affect the kidneys, heart, lungs, brain, blood vessels, and other organs, leading to a wide range of symptoms such as kidney dysfunction, chest pain, shortness of breath, seizures, and anemia. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic, environmental, and hormonal factors. Treatment typically involves medications to suppress the immune system and manage symptoms, and may require long-term management by a team of healthcare professionals.

Gamma-globulins are a type of protein found in the blood serum, specifically a class of immunoglobulins (antibodies) known as IgG. They are the most abundant type of antibody and provide long-term defense against bacterial and viral infections. Gamma-globulins can also be referred to as "gamma globulin" or "gamma immune globulins."

These proteins are produced by B cells, a type of white blood cell, in response to an antigen (a foreign substance that triggers an immune response). IgG gamma-globulins have the ability to cross the placenta and provide passive immunity to the fetus. They can be measured through various medical tests such as serum protein electrophoresis (SPEP) or immunoelectrophoresis, which are used to diagnose and monitor conditions related to immune system disorders, such as multiple myeloma or primary immunodeficiency diseases.

In addition, gamma-globulins can be administered therapeutically in the form of intravenous immunoglobulin (IVIG) to provide passive immunity for patients with immunodeficiencies, autoimmune disorders, or infectious diseases.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

An antigen-antibody complex is a type of immune complex that forms when an antibody binds to a specific antigen. An antigen is any substance that triggers an immune response, while an antibody is a protein produced by the immune system to neutralize or destroy foreign substances like antigens.

When an antibody binds to an antigen, it forms a complex that can be either soluble or insoluble. Soluble complexes are formed when the antigen is small and can move freely through the bloodstream. Insoluble complexes, on the other hand, are formed when the antigen is too large to move freely, such as when it is part of a bacterium or virus.

The formation of antigen-antibody complexes plays an important role in the immune response. Once formed, these complexes can be recognized and cleared by other components of the immune system, such as phagocytes, which help to prevent further damage to the body. However, in some cases, the formation of large numbers of antigen-antibody complexes can lead to inflammation and tissue damage, contributing to the development of certain autoimmune diseases.

Steroids, also known as corticosteroids, are a type of hormone that the adrenal gland produces in your body. They have many functions, such as controlling the balance of salt and water in your body and helping to reduce inflammation. Steroids can also be synthetically produced and used as medications to treat a variety of conditions, including allergies, asthma, skin conditions, and autoimmune disorders.

Steroid medications are available in various forms, such as oral pills, injections, creams, and inhalers. They work by mimicking the effects of natural hormones produced by your body, reducing inflammation and suppressing the immune system's response to prevent or reduce symptoms. However, long-term use of steroids can have significant side effects, including weight gain, high blood pressure, osteoporosis, and increased risk of infections.

It is important to note that anabolic steroids are a different class of drugs that are sometimes abused for their muscle-building properties. These steroids are synthetic versions of the male hormone testosterone and can have serious health consequences when taken in large doses or without medical supervision.

Nephritis is a medical term that refers to inflammation of the kidneys, specifically affecting the glomeruli - the tiny filtering units inside the kidneys. The condition can cause damage to the glomeruli, leading to impaired kidney function and the leakage of protein and blood into the urine.

Nephritis can result from a variety of causes, including infections, autoimmune disorders, and exposure to certain medications or toxins. Depending on the severity and underlying cause, nephritis may be treated with medications, dietary modifications, or other therapies aimed at reducing inflammation and preserving kidney function. In severe cases, hospitalization and more intensive treatments may be necessary.

Leukocytoclastic vasculitis, cutaneous is a type of vasculitis that is limited to the skin. Vasculitis refers to inflammation of the blood vessels, which can cause damage to the vessel walls and impair blood flow to various tissues in the body. In leukocytoclastic vasculitis, the small blood vessels (capillaries and venules) in the skin become inflamed, leading to damage and destruction of the vessel walls.

The term "leukocytoclastic" refers to the presence of nuclear debris from white blood cells (leukocytes) that have been destroyed within the affected blood vessels. This type of vasculitis is often associated with the deposition of immune complexes (formed by the interaction between antibodies and antigens) in the walls of the blood vessels, which triggers an inflammatory response.

Cutaneous leukocytoclastic vasculitis typically presents as palpable purpura (small to large, raised, purple or red spots on the skin), usually located on the lower extremities, but can also affect other areas of the body. Other symptoms may include burning or itching sensations in the affected area, and in some cases, ulcers or necrosis (tissue death) may occur.

The diagnosis of cutaneous leukocytoclastic vasculitis is typically made based on clinical presentation, laboratory tests, and histopathological examination of a skin biopsy specimen. Treatment usually involves addressing any underlying causes or triggers, as well as managing symptoms with medications such as corticosteroids or immunosuppressive agents.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Hematologic diseases, also known as hematological disorders, refer to a group of conditions that affect the production, function, or destruction of blood cells or blood-related components, such as plasma. These diseases can affect erythrocytes (red blood cells), leukocytes (white blood cells), and platelets (thrombocytes), as well as clotting factors and hemoglobin.

Hematologic diseases can be broadly categorized into three main types:

1. Anemia: A condition characterized by a decrease in the total red blood cell count, hemoglobin, or hematocrit, leading to insufficient oxygen transport to tissues and organs. Examples include iron deficiency anemia, sickle cell anemia, and aplastic anemia.
2. Leukemia and other disorders of white blood cells: These conditions involve the abnormal production or function of leukocytes, which can lead to impaired immunity and increased susceptibility to infections. Examples include leukemias (acute lymphoblastic leukemia, chronic myeloid leukemia), lymphomas, and myelodysplastic syndromes.
3. Platelet and clotting disorders: These diseases affect the production or function of platelets and clotting factors, leading to abnormal bleeding or clotting tendencies. Examples include hemophilia, von Willebrand disease, thrombocytopenia, and disseminated intravascular coagulation (DIC).

Hematologic diseases can have various causes, including genetic defects, infections, autoimmune processes, environmental factors, or malignancies. Proper diagnosis and management of these conditions often require the expertise of hematologists, who specialize in diagnosing and treating disorders related to blood and its components.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

HELLP syndrome is a serious complication in pregnancy, characterized by Hemolysis (the breakdown of red blood cells), Elevated Liver enzymes, and Low Platelet count. It is often considered a variant of severe preeclampsia or eclampsia, although it can also occur without these conditions.

The symptoms of HELLP syndrome include headache, nausea and vomiting, upper right abdominal pain, and visual disturbances. It can lead to serious complications for both the mother and the baby, such as liver failure, placental abruption, disseminated intravascular coagulation (DIC), and even death if not promptly diagnosed and treated.

The exact cause of HELLP syndrome is not known, but it is thought to be related to problems with the blood vessels that supply the placenta. Treatment typically involves delivering the baby as soon as possible, even if the baby is premature. Women who have had HELLP syndrome are at increased risk for complications in future pregnancies.

Fc receptors (FcRs) are specialized proteins found on the surface of various immune cells, including neutrophils, monocytes, macrophages, eosinophils, basophils, mast cells, and B lymphocytes. They play a crucial role in the immune response by recognizing and binding to the Fc region of antibodies (IgG, IgA, and IgE) after they have interacted with their specific antigens.

FcRs can be classified into several types based on the class of antibody they bind:

1. FcγRs - bind to the Fc region of IgG antibodies
2. FcαRs - bind to the Fc region of IgA antibodies
3. FcεRs - bind to the Fc region of IgE antibodies

The binding of antibodies to Fc receptors triggers various cellular responses, such as phagocytosis, degranulation, and antibody-dependent cellular cytotoxicity (ADCC), which contribute to the elimination of pathogens, immune complexes, and other foreign substances. Dysregulation of Fc receptor function has been implicated in several diseases, including autoimmune disorders and allergies.

The platelet glycoprotein GPIIb-IIIa complex, also known as integrin αIIbβ3 or CD41/CD61, is a heterodimeric transmembrane receptor found on the surface of platelets and megakaryocytes. It plays a crucial role in platelet aggregation and thrombus formation during hemostasis and pathological conditions such as arterial thrombosis.

The GPIIb-IIIa complex is composed of two non-covalently associated subunits, GPIIb (αIIb or CD41) and IIIa (β3 or CD61). Upon platelet activation by various agonists like ADP, thrombin, or collagen, the GPIIb-IIIa complex undergoes a conformational change that allows it to bind fibrinogen, von Willebrand factor, and other adhesive proteins. This binding event leads to platelet aggregation and the formation of a hemostatic plug or pathological thrombus.

Inhibition of the GPIIb-IIIa complex has been a target for antiplatelet therapy in the prevention and treatment of arterial thrombosis, such as myocardial infarction and stroke. Several pharmacological agents, including monoclonal antibodies and small molecule antagonists, have been developed to block this complex and reduce platelet aggregation.

Idiopathic interstitial pneumonias (IIPs) are a group of rare lung diseases with no known cause, characterized by inflammation and scarring (fibrosis) of the lung tissue. The term "idiopathic" means that the cause is unknown, and "interstitial" refers to the spaces between the air sacs in the lungs where the inflammation and scarring occur.

IIPs are classified into several subtypes based on their clinical, radiological, and pathological features. These include:

1. Idiopathic Pulmonary Fibrosis (IPF): This is the most common and aggressive form of IIP, characterized by progressive scarring of the lung tissue, which leads to difficulty breathing and decreased lung function over time.
2. Nonspecific Interstitial Pneumonia (NSIP): This subtype is characterized by varying degrees of inflammation and fibrosis in the lung tissue. NSIP can be idiopathic or associated with connective tissue diseases.
3. Respiratory Bronchiolitis-Interstitial Lung Disease (RB-ILD): This subtype primarily affects smokers and is characterized by inflammation of the small airways and surrounding lung tissue.
4. Desquamative Interstitial Pneumonia (DIP): This subtype is also more common in smokers and is characterized by accumulation of pigmented macrophages in the lung tissue.
5. Cryptogenic Organizing Pneumonia (COP): This subtype is characterized by the formation of fibrous masses in the small airways and alveoli, leading to cough and shortness of breath.
6. Acute Interstitial Pneumonia (AIP)/Acute Respiratory Distress Syndrome (ARDS): This subtype is a severe form of IIP that can rapidly progress to respiratory failure and requires immediate medical attention.

The diagnosis of IIPs typically involves a combination of clinical evaluation, imaging studies, and lung biopsy. Treatment options may include corticosteroids, immunosuppressive medications, and oxygen therapy, depending on the severity and subtype of the disease.

Leg dermatoses is a general term that refers to various skin conditions affecting the legs. This can include a wide range of inflammatory, infectious, or degenerative diseases that cause symptoms such as redness, itching, scaling, blistering, or pigmentation changes on the leg skin. Examples of specific leg dermatoses include stasis dermatitis, venous eczema, contact dermatitis, lichen planus, psoriasis, and cellulitis among others. Accurate diagnosis usually requires a thorough examination and sometimes a biopsy to determine the specific type of dermatosis and appropriate treatment.

The spleen is an organ in the upper left side of the abdomen, next to the stomach and behind the ribs. It plays multiple supporting roles in the body:

1. It fights infection by acting as a filter for the blood. Old red blood cells are recycled in the spleen, and platelets and white blood cells are stored there.
2. The spleen also helps to control the amount of blood in the body by removing excess red blood cells and storing platelets.
3. It has an important role in immune function, producing antibodies and removing microorganisms and damaged red blood cells from the bloodstream.

The spleen can be removed without causing any significant problems, as other organs take over its functions. This is known as a splenectomy and may be necessary if the spleen is damaged or diseased.

Pulmonary fibrosis is a specific type of lung disease that results from the thickening and scarring of the lung tissues, particularly those in the alveoli (air sacs) and interstitium (the space around the air sacs). This scarring makes it harder for the lungs to properly expand and transfer oxygen into the bloodstream, leading to symptoms such as shortness of breath, coughing, fatigue, and eventually respiratory failure. The exact cause of pulmonary fibrosis can vary, with some cases being idiopathic (without a known cause) or related to environmental factors, medications, medical conditions, or genetic predisposition.

Splenic diseases refer to a range of medical conditions that affect the structure, function, or health of the spleen. The spleen is an organ located in the upper left quadrant of the abdomen, which plays a vital role in filtering the blood and fighting infections. Some common splenic diseases include:

1. Splenomegaly: Enlargement of the spleen due to various causes such as infections, liver disease, blood disorders, or cancer.
2. Hypersplenism: Overactivity of the spleen leading to excessive removal of blood cells from circulation, causing anemia, leukopenia, or thrombocytopenia.
3. Splenic infarction: Partial or complete blockage of the splenic artery or its branches, resulting in tissue death and potential organ dysfunction.
4. Splenic rupture: Traumatic or spontaneous tearing of the spleen capsule, causing internal bleeding and potentially life-threatening conditions.
5. Infections: Bacterial (e.g., sepsis, tuberculosis), viral (e.g., mononucleosis, cytomegalovirus), fungal (e.g., histoplasmosis), or parasitic (e.g., malaria) infections can affect the spleen and cause various symptoms.
6. Hematologic disorders: Conditions such as sickle cell disease, thalassemia, hemolytic anemias, lymphomas, leukemias, or myeloproliferative neoplasms can involve the spleen and lead to its enlargement or dysfunction.
7. Autoimmune diseases: Conditions like rheumatoid arthritis, systemic lupus erythematosus, or vasculitis can affect the spleen and cause various symptoms.
8. Cancers: Primary (e.g., splenic tumors) or secondary (e.g., metastatic cancer from other organs) malignancies can involve the spleen and lead to its enlargement, dysfunction, or rupture.
9. Vascular abnormalities: Conditions such as portal hypertension, Budd-Chiari syndrome, or splenic vein thrombosis can affect the spleen and cause various symptoms.
10. Trauma: Accidental or intentional injuries to the spleen can lead to bleeding, infection, or organ dysfunction.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Antibody specificity refers to the ability of an antibody to bind to a specific epitope or antigenic determinant on an antigen. Each antibody has a unique structure that allows it to recognize and bind to a specific region of an antigen, typically a small portion of the antigen's surface made up of amino acids or sugar residues. This highly specific binding is mediated by the variable regions of the antibody's heavy and light chains, which form a pocket that recognizes and binds to the epitope.

The specificity of an antibody is determined by its unique complementarity-determining regions (CDRs), which are loops of amino acids located in the variable domains of both the heavy and light chains. The CDRs form a binding site that recognizes and interacts with the epitope on the antigen. The precise fit between the antibody's binding site and the epitope is critical for specificity, as even small changes in the structure of either can prevent binding.

Antibody specificity is important in immune responses because it allows the immune system to distinguish between self and non-self antigens. This helps to prevent autoimmune reactions where the immune system attacks the body's own cells and tissues. Antibody specificity also plays a crucial role in diagnostic tests, such as ELISA assays, where antibodies are used to detect the presence of specific antigens in biological samples.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

A "Blood Cell Count" is a medical laboratory test that measures the number of red blood cells (RBCs), white blood cells (WBCs), and platelets in a sample of blood. This test is often used as a part of a routine check-up or to help diagnose various medical conditions, such as anemia, infection, inflammation, and many others.

The RBC count measures the number of oxygen-carrying cells in the blood, while the WBC count measures the number of immune cells that help fight infections. The platelet count measures the number of cells involved in clotting. Abnormal results in any of these counts may indicate an underlying medical condition and further testing may be required for diagnosis and treatment.

I'm sorry for any confusion, but "Oxyquinoline" does not have a specific medical definition as it is not a widely recognized medical term or a medication used in human healthcare. Oxyquinoline is an organic compound that contains a quinoline ring substituted with an alcohol group (hydroxyl) at position 8. It has been used in the past as a disinfectant and antiseptic, but it's not common in modern medical practice.

If you have any questions about medical terminology or concepts, please provide more context so I can offer a more accurate and helpful response.

Hydrazines are not a medical term, but rather a class of organic compounds containing the functional group N-NH2. They are used in various industrial and chemical applications, including the production of polymers, pharmaceuticals, and agrochemicals. However, some hydrazines have been studied for their potential therapeutic uses, such as in the treatment of cancer and cardiovascular diseases. Exposure to high levels of hydrazines can be toxic and may cause damage to the liver, kidneys, and central nervous system. Therefore, medical professionals should be aware of the potential health hazards associated with hydrazine exposure.

Dilated cardiomyopathy (DCM) is a type of cardiomyopathy characterized by the enlargement and weakened contraction of the heart's main pumping chamber (the left ventricle). This enlargement and weakness can lead to symptoms such as shortness of breath, fatigue, and fluid retention. DCM can be caused by various factors including genetics, viral infections, alcohol and drug abuse, and other medical conditions like high blood pressure and diabetes. It is important to note that this condition can lead to heart failure if left untreated.

T-lymphocytopenia, idiopathic CD4-positive, also known as Idiopathic CD4 Lymphopenia (ICL), is a rare medical condition characterized by a significant decrease in the number of CD4+ T lymphocytes in the peripheral blood without an identifiable cause. CD4+ T cells are crucial for immune function and protection against certain types of infections, particularly those caused by viruses such as HIV.

ICL is typically defined as a CD4+ T-lymphocyte count below 300 cells/μL in the absence of HIV infection or any other known immunodeficiency disorder. The exact cause of ICL remains unknown, although it has been associated with genetic factors and autoimmune disorders.

People with ICL may be at increased risk for certain types of infections, such as opportunistic infections, which can occur when the immune system is weakened. However, the severity and frequency of infections in individuals with ICL are generally less than those seen in people with HIV-associated CD4 lymphopenia.

Regular monitoring of CD4+ T-lymphocyte counts and appropriate management of any infections that occur are important for people with ICL to maintain their overall health and well-being.

Immune system diseases, also known as immunological disorders or autoimmune diseases, refer to a group of conditions in which the immune system mistakenly attacks and damages healthy tissues in the body. The immune system is designed to protect the body from harmful substances such as viruses, bacteria, and toxins. However, in immune system diseases, the immune system fails to distinguish between these harmful substances and the body's own cells, leading to an overactive or misdirected response.

There are several types of immune system diseases, including:

1. Allergies: An abnormal immune response to harmless substances such as pollen, dust mites, or certain foods.
2. Autoimmune disorders: A group of conditions in which the immune system attacks healthy tissues, such as rheumatoid arthritis, lupus, and multiple sclerosis.
3. Immunodeficiency disorders: Conditions that weaken the immune system, making it harder for the body to fight off infections, such as HIV/AIDS or primary immunodeficiency diseases.
4. Autoinflammatory disorders: A group of conditions characterized by recurrent episodes of inflammation due to abnormal activation of the immune system, such as familial Mediterranean fever and cryopyrin-associated periodic syndromes.
5. Transplant rejection: A response in which the immune system attacks and rejects transplanted organs or tissues.

Immune system diseases can cause a wide range of symptoms, depending on the specific condition and the severity of the disease. Treatment may involve medications to suppress the immune system, as well as other therapies to manage symptoms and prevent complications.

A syndrome, in medical terms, is a set of symptoms that collectively indicate or characterize a disease, disorder, or underlying pathological process. It's essentially a collection of signs and/or symptoms that frequently occur together and can suggest a particular cause or condition, even though the exact physiological mechanisms might not be fully understood.

For example, Down syndrome is characterized by specific physical features, cognitive delays, and other developmental issues resulting from an extra copy of chromosome 21. Similarly, metabolic syndromes like diabetes mellitus type 2 involve a group of risk factors such as obesity, high blood pressure, high blood sugar, and abnormal cholesterol or triglyceride levels that collectively increase the risk of heart disease, stroke, and diabetes.

It's important to note that a syndrome is not a specific diagnosis; rather, it's a pattern of symptoms that can help guide further diagnostic evaluation and management.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Staphylococcal Protein A (SpA) is a cell wall-associated protein found on many strains of the bacterium Staphylococcus aureus. It plays an important role in the pathogenesis of staphylococcal infections. SpA has several domains that allow it to bind to various host proteins, including immunoglobulins (Igs), complement components, and fibrinogen.

The protein A's ability to bind to the Fc region of Igs, particularly IgG, enables it to inhibit phagocytosis by masking the antibodies' binding sites, thus helping the bacterium evade the host immune system. Additionally, SpA can activate complement component C1 and initiate the classical complement pathway, leading to the release of anaphylatoxins and the formation of the membrane attack complex, which can cause tissue damage.

Furthermore, SpA's binding to fibrinogen promotes bacterial adherence and colonization of host tissues, contributing to the establishment of infection. Overall, Staphylococcal Protein A is a crucial virulence factor in S. aureus infections, making it an important target for the development of novel therapeutic strategies.

Glucocorticoids are a class of steroid hormones that are naturally produced in the adrenal gland, or can be synthetically manufactured. They play an essential role in the metabolism of carbohydrates, proteins, and fats, and have significant anti-inflammatory effects. Glucocorticoids suppress immune responses and inflammation by inhibiting the release of inflammatory mediators from various cells, such as mast cells, eosinophils, and lymphocytes. They are frequently used in medical treatment for a wide range of conditions, including allergies, asthma, rheumatoid arthritis, dermatological disorders, and certain cancers. Prolonged use or high doses of glucocorticoids can lead to several side effects, such as weight gain, mood changes, osteoporosis, and increased susceptibility to infections.

CD20 is not a medical definition of an antigen, but rather it is a cell surface marker that helps identify a specific type of white blood cell called B-lymphocytes or B-cells. These cells are part of the adaptive immune system and play a crucial role in producing antibodies to fight off infections.

CD20 is a protein found on the surface of mature B-cells, and it is used as a target for monoclonal antibody therapies in the treatment of certain types of cancer and autoimmune diseases. Rituximab is an example of a monoclonal antibody that targets CD20 and is used to treat conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

While CD20 itself is not an antigen, it can be recognized by the immune system as a foreign substance when a monoclonal antibody such as rituximab binds to it. This binding can trigger an immune response, leading to the destruction of the B-cells that express CD20 on their surface.

Aplastic anemia is a medical condition characterized by pancytopenia (a decrease in all three types of blood cells: red blood cells, white blood cells, and platelets) due to the failure of bone marrow to produce new cells. It is called "aplastic" because the bone marrow becomes hypocellular or "aplastic," meaning it contains few or no blood-forming stem cells.

The condition can be acquired or inherited, with acquired aplastic anemia being more common. Acquired aplastic anemia can result from exposure to toxic chemicals, radiation, drugs, viral infections, or autoimmune disorders. Inherited forms of the disease include Fanconi anemia and dyskeratosis congenita.

Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, easy bruising or bleeding, frequent infections, and fever. Treatment options for aplastic anemia depend on the severity of the condition and its underlying cause. They may include blood transfusions, immunosuppressive therapy, and stem cell transplantation.

Quinidine is a Class IA antiarrhythmic medication that is primarily used to treat and prevent various types of cardiac arrhythmias (abnormal heart rhythms). It works by blocking the rapid sodium channels in the heart, which helps to slow down the conduction of electrical signals within the heart and stabilize its rhythm.

Quinidine is derived from the bark of the Cinchona tree and has been used for centuries as a treatment for malaria. However, its antiarrhythmic properties were discovered later, and it became an important medication in cardiology.

In addition to its use in treating arrhythmias, quinidine may also be used off-label for other indications such as the treatment of nocturnal leg cramps or myasthenia gravis. It is available in various forms, including tablets and injectable solutions.

It's important to note that quinidine has a narrow therapeutic index, meaning that there is only a small difference between an effective dose and a toxic one. Therefore, it must be carefully monitored to ensure that the patient is receiving a safe and effective dose. Common side effects of quinidine include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, as well as visual disturbances, headache, and dizziness. More serious side effects can include QT prolongation, which can lead to dangerous arrhythmias, and hypersensitivity reactions.

Integrin β3 is a subunit of certain integrin heterodimers, which are transmembrane receptors that mediate cell-cell and cell-extracellular matrix (ECM) adhesion. Integrin β3 combines with either integrin αv (to form the integrin αvβ3) or integrin αIIb (to form the integrin αIIbβ3). These integrins are involved in various cellular processes, including platelet aggregation, angiogenesis, and tumor metastasis.

Integrin αIIbβ3 is primarily expressed on platelets and mediates platelet aggregation by binding to fibrinogen, von Willebrand factor, and other adhesive proteins in the ECM. Integrin αvβ3 is widely expressed in various cell types and participates in diverse functions such as cell migration, proliferation, differentiation, and survival. It binds to a variety of ECM proteins, including fibronectin, vitronectin, and osteopontin, as well as to soluble ligands like vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β).

Dysregulation of integrin β3 has been implicated in several pathological conditions, such as thrombosis, atherosclerosis, tumor metastasis, and inflammatory diseases.

Hemorrhagic disorders are medical conditions characterized by abnormal bleeding due to impaired blood clotting. This can result from deficiencies in coagulation factors, platelet dysfunction, or the use of medications that interfere with normal clotting processes. Examples include hemophilia, von Willebrand disease, and disseminated intravascular coagulation (DIC). Treatment often involves replacing the missing clotting factor or administering medications to help control bleeding.

Anticardiolipin antibodies are a type of autoantibody that targets and binds to cardiolipin, a phospholipid component found in the inner mitochondrial membrane of cells. These antibodies are clinically significant because they have been associated with a variety of autoimmune disorders, including antiphospholipid syndrome (APS).

APS is a condition characterized by recurrent blood clots, pregnancy losses, and thrombocytopenia (low platelet count). Anticardiolipin antibodies are one of the three main types of autoantibodies found in APS, along with lupus anticoagulant and anti-β2 glycoprotein I antibodies.

The presence of high levels of anticardiolipin antibodies in the blood can lead to abnormal blood clotting, which can cause serious complications such as deep vein thrombosis, pulmonary embolism, and stroke. Anticardiolipin antibodies can also contribute to pregnancy losses by causing placental insufficiency or abnormal blood clotting in the placenta.

Anticardiolipin antibodies are typically detected through a blood test that measures their levels in the serum. A positive result is usually confirmed with a second test performed at least 12 weeks later to establish persistence. Treatment for anticardiolipin antibody-related disorders typically involves anticoagulation therapy to prevent blood clots and other complications.

IGA glomerulonephritis (also known as Berger's disease) is a type of glomerulonephritis, which is a condition characterized by inflammation of the glomeruli, the tiny filtering units in the kidneys. In IgA glomerulonephritis, the immune system produces an abnormal amount of IgA antibodies, which deposit in the glomeruli and cause inflammation. This can lead to symptoms such as blood in the urine, protein in the urine, and swelling in the legs and feet. In some cases, it can also lead to kidney failure. The exact cause of IgA glomerulonephritis is not known, but it is often associated with other conditions such as infections, autoimmune diseases, and certain medications.

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in the blood. These antibodies are directed against phospholipids, a type of fat molecule found in cell membranes and plasma lipoproteins. The presence of these antibodies can lead to abnormal blood clotting, which can cause serious complications such as stroke, heart attack, deep vein thrombosis, and pulmonary embolism.

APS can occur either on its own (primary APS) or in conjunction with other autoimmune disorders, such as systemic lupus erythematosus (secondary APS). The exact cause of APS is not fully understood, but it is believed to involve a combination of genetic and environmental factors.

Symptoms of APS can vary widely depending on the location and severity of the blood clots. They may include:

* Recurrent miscarriages or stillbirths
* Blood clots in the legs, lungs, or other parts of the body
* Skin ulcers or lesions
* Headaches, seizures, or stroke-like symptoms
* Kidney problems
* Heart valve abnormalities

Diagnosis of APS typically involves blood tests to detect the presence of antiphospholipid antibodies. Treatment may include medications to prevent blood clots, such as anticoagulants and antiplatelet agents, as well as management of any underlying autoimmune disorders.

Complement C3 is a protein that plays a central role in the complement system, which is a part of the immune system that helps to clear pathogens and damaged cells from the body. Complement C3 can be activated through three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. Once activated, it breaks down into two fragments, C3a and C3b.

C3a is an anaphylatoxin that helps to recruit immune cells to the site of infection or injury, while C3b plays a role in opsonization, which is the process of coating pathogens or damaged cells with proteins to make them more recognizable to the immune system. Additionally, C3b can also activate the membrane attack complex (MAC), which forms a pore in the membrane of target cells leading to their lysis or destruction.

In summary, Complement C3 is an important protein in the complement system that helps to identify and eliminate pathogens and damaged cells from the body through various mechanisms.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

Prospective studies, also known as longitudinal studies, are a type of cohort study in which data is collected forward in time, following a group of individuals who share a common characteristic or exposure over a period of time. The researchers clearly define the study population and exposure of interest at the beginning of the study and follow up with the participants to determine the outcomes that develop over time. This type of study design allows for the investigation of causal relationships between exposures and outcomes, as well as the identification of risk factors and the estimation of disease incidence rates. Prospective studies are particularly useful in epidemiology and medical research when studying diseases with long latency periods or rare outcomes.

Nephrotic syndrome is a group of symptoms that indicate kidney damage, specifically damage to the glomeruli—the tiny blood vessel clusters in the kidneys that filter waste and excess fluids from the blood. The main features of nephrotic syndrome are:

1. Proteinuria (excess protein in urine): Large amounts of a protein called albumin leak into the urine due to damaged glomeruli, which can't properly filter proteins. This leads to low levels of albumin in the blood, causing fluid buildup and swelling.
2. Hypoalbuminemia (low blood albumin levels): As albumin leaks into the urine, the concentration of albumin in the blood decreases, leading to hypoalbuminemia. This can cause edema (swelling), particularly in the legs, ankles, and feet.
3. Edema (fluid retention and swelling): With low levels of albumin in the blood, fluids move into the surrounding tissues, causing swelling or puffiness. The swelling is most noticeable around the eyes, face, hands, feet, and abdomen.
4. Hyperlipidemia (high lipid/cholesterol levels): The kidneys play a role in regulating lipid metabolism. Damage to the glomeruli can lead to increased lipid production and high cholesterol levels in the blood.

Nephrotic syndrome can result from various underlying kidney diseases, such as minimal change disease, membranous nephropathy, or focal segmental glomerulosclerosis. Treatment depends on the underlying cause and may include medications to control inflammation, manage high blood pressure, and reduce proteinuria. In some cases, dietary modifications and lifestyle changes are also recommended.

Dipyridamole is a medication that belongs to a class of drugs called antiplatelet agents. It works by preventing platelets in your blood from sticking together to form clots. Dipyridamole is often used in combination with aspirin to prevent stroke and other complications in people who have had a heart valve replacement or a type of irregular heartbeat called atrial fibrillation.

Dipyridamole can also be used as a stress agent in myocardial perfusion imaging studies, which are tests used to evaluate blood flow to the heart. When used for this purpose, dipyridamole is given intravenously and works by dilating the blood vessels in the heart, allowing more blood to flow through them and making it easier to detect areas of reduced blood flow.

The most common side effects of dipyridamole include headache, dizziness, and gastrointestinal symptoms such as diarrhea, nausea, and vomiting. In rare cases, dipyridamole can cause more serious side effects, such as allergic reactions, abnormal heart rhythms, or low blood pressure. It is important to take dipyridamole exactly as directed by your healthcare provider and to report any unusual symptoms or side effects promptly.

An exchange transfusion of whole blood is a medical procedure in which a patient's blood is gradually replaced with donor whole blood. This procedure is typically performed in newborns or infants who have severe jaundice caused by excessive levels of bilirubin, a yellowish pigment that forms when hemoglobin from red blood cells breaks down.

During an exchange transfusion, the baby's blood is removed through a vein or artery and replaced with donor whole blood through another vein or artery. The process is repeated several times until a significant portion of the baby's blood has been exchanged with donor blood. This helps to reduce the levels of bilirubin in the baby's blood, which can help prevent or treat brain damage caused by excessive bilirubin.

Exchange transfusions are typically performed in a neonatal intensive care unit (NICU) and require close monitoring by a team of healthcare professionals. The procedure carries some risks, including infection, bleeding, and changes in blood pressure or heart rate. However, it can be a lifesaving treatment for newborns with severe jaundice who are at risk of developing serious complications.

A blood component transfusion is the process of transferring a specific component of donated blood into a recipient's bloodstream. Blood components include red blood cells, plasma, platelets, and cryoprecipitate (a fraction of plasma that contains clotting factors). These components can be separated from whole blood and stored separately to allow for targeted transfusions based on the individual needs of the patient.

For example, a patient who is anemic may only require a red blood cell transfusion, while a patient with severe bleeding may need both red blood cells and plasma to replace lost volume and clotting factors. Platelet transfusions are often used for patients with low platelet counts or platelet dysfunction, and cryoprecipitate is used for patients with factor VIII or fibrinogen deficiencies.

Blood component transfusions must be performed under strict medical supervision to ensure compatibility between the donor and recipient blood types and to monitor for any adverse reactions. Proper handling, storage, and administration of blood components are also critical to ensure their safety and efficacy.

Immunoglobulin M (IgM) is a type of antibody that is primarily found in the blood and lymph fluid. It is the first antibody to be produced in response to an initial exposure to an antigen, making it an important part of the body's primary immune response. IgM antibodies are large molecules that are composed of five basic units, giving them a pentameric structure. They are primarily found on the surface of B cells as membrane-bound immunoglobulins (mlgM), where they function as receptors for antigens. Once an mlgM receptor binds to an antigen, it triggers the activation and differentiation of the B cell into a plasma cell that produces and secretes large amounts of soluble IgM antibodies.

IgM antibodies are particularly effective at agglutination (clumping) and complement activation, which makes them important in the early stages of an immune response to help clear pathogens from the bloodstream. However, they are not as stable or long-lived as other types of antibodies, such as IgG, and their levels tend to decline after the initial immune response has occurred.

In summary, Immunoglobulin M (IgM) is a type of antibody that plays a crucial role in the primary immune response to antigens by agglutination and complement activation. It is primarily found in the blood and lymph fluid, and it is produced by B cells after they are activated by an antigen.

Immunoglobulin (Ig) Fab fragments are the antigen-binding portions of an antibody that result from the digestion of the whole antibody molecule by enzymes such as papain. An antibody, also known as an immunoglobulin, is a Y-shaped protein produced by the immune system to identify and neutralize foreign substances like bacteria, viruses, or toxins. The antibody has two identical antigen-binding sites, located at the tips of the two shorter arms, which can bind specifically to a target antigen.

Fab fragments are formed when an antibody is cleaved by papain, resulting in two Fab fragments and one Fc fragment. Each Fab fragment contains one antigen-binding site, composed of a variable region (Fv) and a constant region (C). The Fv region is responsible for the specificity and affinity of the antigen binding, while the C region contributes to the effector functions of the antibody.

Fab fragments are often used in various medical applications, such as immunodiagnostics and targeted therapies, due to their ability to bind specifically to target antigens without triggering an immune response or other effector functions associated with the Fc region.

A Severity of Illness Index is a measurement tool used in healthcare to assess the severity of a patient's condition and the risk of mortality or other adverse outcomes. These indices typically take into account various physiological and clinical variables, such as vital signs, laboratory values, and co-morbidities, to generate a score that reflects the patient's overall illness severity.

Examples of Severity of Illness Indices include the Acute Physiology and Chronic Health Evaluation (APACHE) system, the Simplified Acute Physiology Score (SAPS), and the Mortality Probability Model (MPM). These indices are often used in critical care settings to guide clinical decision-making, inform prognosis, and compare outcomes across different patient populations.

It is important to note that while these indices can provide valuable information about a patient's condition, they should not be used as the sole basis for clinical decision-making. Rather, they should be considered in conjunction with other factors, such as the patient's overall clinical presentation, treatment preferences, and goals of care.

Antinuclear antibodies (ANA) are a type of autoantibody that target structures found in the nucleus of a cell. These antibodies are produced by the immune system and attack the body's own cells and tissues, leading to inflammation and damage. The presence of ANA is often used as a marker for certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, scleroderma, and polymyositis.

ANA can be detected through a blood test called the antinuclear antibody test. A positive result indicates the presence of ANA in the blood, but it does not necessarily mean that a person has an autoimmune disease. Further testing is usually needed to confirm a diagnosis and determine the specific type of autoantibodies present.

It's important to note that ANA can also be found in healthy individuals, particularly as they age. Therefore, the test results should be interpreted in conjunction with other clinical findings and symptoms.

Idiopathic thrombocytopenic purpura. Dapsone is effective and safe for adjunctive glucocorticoid-sparing treatment of persons ... with idiopathic thrombocytopenic purpura and is preferred over danazol or interferon alpha in those people with antinuclear ... "Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review ... Liang SE, Hoffmann R, Peterson E, Soter NA (2019). "Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune ...
Many cases of immune thrombocytopenic purpura (ITP), also known as idiopathic thrombocytopenic purpura, can be left untreated, ... Immune thrombocytopenic purpura Thrombotic thrombocytopenic purpura Hemolytic-uremic syndrome Disseminated intravascular ... "Idiopathic thrombocytopenic purpura (ITP)". MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine. Retrieved 2015 ... "How Is Thrombotic Thrombocytopenic Purpura Treated?". National Heart, Lung, and Blood Institute (NHLBI). U.S. Department of ...
Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966;68:971-9. Warrier I, Lusher JM. Intravenous gamma globulin ... Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids. Am J Pediatr Hematol Oncol ... Intravenous gammaglobulin (Gamimune) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): a two-year follow-up. ... treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med 1984;76:193-8. Warrier IA, Lusher JM. ...
Williams suffers from idiopathic thrombocytopenic purpura. He was first diagnosed with the recurring rare blood disorder in ...
Delgado P, GarcÃa-Zueco JC, Rubio-Félix D, Giralt M (1992). "[Idiopathic thrombocytopenic purpura: present knowledge and future ...
"Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura". Annals of Internal Medicine. 38 (3): 433-69. doi: ... Louis (1947) Thrombocytopenic purpura Harrington, William J.; Sprague, Charles C.; Minnich, Virginia; Moore, Carl V.; Aulvin, ... landmark study involving self-experimentation that showed that low blood platelet counts in idiopathic thrombocytopenic purpura ... in particular thrombocytopenic purpura, thalassemia, and hemoglobinopathies); the relationship between pica and iron deficiency ...
... and Cortisone in Idiopathic Thrombocytopenic Purpura". Journal of the American Medical Association. JAMA. 149 (7): 647-653. doi ...
His specialization is childhood leukemia and idiopathic thrombocytopenic purpura. Lilleyman contributed to the testing of ...
The fourteen-year research conducted on 883 patients of idiopathic thrombocytopenic purpura (Werlhof disease), conducted in ... "Comorbidities of Idiopathic Thrombocytopenic Purpura: A Population-Based Study". Advances in Hematology. 2009: 1-12. doi: ...
For services to the Idiopathic Thrombocytopenic Purpura Support Association. The Reverend Canon Michael John Wedgeworth, lately ...
821 Idiopathic thrombocytopenic purpura Skin lesion James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of ... Drug-induced thrombocytopenic purpura is a skin condition result from a low platelet count due to drug-induced anti-platelet ...
... has been shown to be effective in two major clinical syndromes: idiopathic thrombocytopenic purpura (ITP) and ... November 2007). "Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura". The New England Journal of ... idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulin therapy, or ... Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)" at ClinicalTrials.gov ...
... such as idiopathic thrombocytopenic purpura (ITP; a platelet disorder) and Henoch-Schönlein purpura, also need prompt ... Not all instances of a purpura-like rash are due to meningococcal septicaemia; other possible causes, ...
... idiopathic) thrombocytopenic purpura". Oncology (Williston Park, N.Y.). 23 (8): 704-709. ISSN 0890-9091. PMID 19711585. ... for chronic immune thrombocytopenic purpura Otezla (apremilast) Parsabiv (etelcalcetide) Prolia (denosumab) for postmenopausal ...
Intramuscular injections should not be administered to those with idiopathic thrombocytopenic purpura. Formulations of Solu- ... Hematology: acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura, secondary thrombocytopenia, ... Nephrology: nephrotic syndrome, idiopathic type or secondary to lupus nephritis. Neurology: multiple sclerosis. Ophthalmology: ...
When Aiden Spencer becomes ill with Idiopathic thrombocytopenic purpura, Maggie treats him. Soon after, Maggie and Steve find ...
... exhibits similarities to idiopathic thrombocytopenic purpura (ITP) but differs in pathogenesis. The affected age range ...
Immune thrombocytopenic purpura (ITP), sometimes called idiopathic thrombocytopenic purpura is a condition in which ... "A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura". Blood. 102 (13): 4306-11. doi ... "Immune Thrombocytopenic Purpura". The Lecturio Medical Concept Library. Retrieved 27 July 2021. McQuilten ZK, Wood EM, Savoia H ... Anti-platelet autoantibodies in a pregnant woman with immune thrombocytopenic purpura will attack the patient's own platelets ...
"Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura". Blood. 111 (3): 1029- ...
"Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura". Clinical and ...
At four years old, she was hospitalized and diagnosed with idiopathic thrombocytopenic purpura (ITP). She graduated from ...
... is indicated as a potential treatment for chronic idiopathic (immune) thrombocytopenic purpura (ITP). Romiplostim ... February 2008). "Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised ... durable platelet response in nonsplenectomized or splenectomized adults with chronic immune thrombocytopenic purpura. ...
Damien Gurganious died from idiopathic thrombocytopenic purpura, a rare autoimmune disorder on November 24, 2014. This caused ...
In 1916 Schloffer became the first to remove a spleen for idiopathic thrombocytopenic purpura (ITP). His student Paul Kaznelson ... Splenogene thrombolytische Purpura." Wien Klin Wochenschr. 29: 1451-4. v t e (Articles with short description, Short ...
lupus erythematosus, autoimmune hemolytic anemia, and idiopathic thrombocytopenic purpura have been reported with PNP- ...
... idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome" (PDF). Mayo Clin. Proc. 78 (11): 1340-6. ... Immune thrombocytopenic purpura is a condition in which platelets are destroyed by an autoimmune process. Platelets are a ... 1992). "[Thrombotic thrombocytopenic purpura achieving complete remission by slow infusion of vincristine]". Rinsho Ketsueki ( ... Its overall phenotype resembles a combination of autoimmune hemolytic anemia and immune thrombocytopenic purpura. Autoimmune ...
Predominant clinical problems include idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), and an ...
In 2012, she announced that she is suffering from idiopathic thrombocytopenic purpura and systemic lupus erythematosus. She is ...
By tradition, the term idiopathic thrombocytopenic purpura is used when the cause is idiopathic, or unknown. However, most ... Thrombocytopenic purpura are purpura associated with a reduction in circulating blood platelets which can result from a variety ... "thrombocytopenic purpura" at Dorland's Medical Dictionary v t e (Articles with short description, Short description is ... Another form is thrombotic thrombocytopenic purpura.[citation needed] Diagnosis is done by the help of symptoms and only blood ...
... idiopathic thrombocytopenic purpura (ITP), sepsis, bone marrow transplant, radiation treatment, organ transplant or surgeries ... Recipients in this category include those with idiopathic thrombocytopenic purpura or drug-induced thrombocytopenia. Platelet ... Platelet transfusions should be avoided in those with thrombotic thrombocytopenic purpura (TTP) because it can worsen ... Thrombocytopenic patients can develop "dry" bleeding, that is, petechiae and ecchymoses only. They will not suffer fatal ...
Treatment of Acute Idiopathic Thrombocytopenic Purpura with High-Dose Methylprednisolone and Immunoglobulin Subject Area: ... In childhood idiopathic thrombocytopenic purpura (ITP), both intravenous high-dose steroids and immunoglobulin treatments have ... Nilka J. Barrios, James R. Humbert, Judy McNeil; Treatment of Acute Idiopathic Thrombocytopenic Purpura with High-Dose ... T Lymphocyte Subsets and Platelet-Associated IgG in Idiopathic Thrombocytopenic Purpura: Effect of Splenectomy Acta Haematol ( ...
Idiopathic Thrombocytopenic Purpura). Read the real story of Parmod Saini and know about how he got relief from this problem. ... Case Study No: 108 , Idiopathic Thrombocytopenic Purpura (ITP) - Parmod Saini. July 29, 2019. December 10, 2019. Dr. Meenakshi ... Case Study No: 108 , Idiopathic Thrombocytopenic Purpura (ITP) - Parmod Saini. Parmod Saini belongs to Ludhiana, a city that ...
Idiopathic Thrombocytopenic Purpura Therapeutics Market. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis by ... The most complete guide to Idiopathic Thrombocytopenic Purpura Therapeutics Market in 2023 ...
U-51is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Idiopathic ... Immune Thrombocytopenic Purpura): Likelihood of Approval. Brought to you by *Idiopathic Thrombocytopenic Purpura (Immune ... Immune Thrombocytopenic Purpura). According to GlobalData, Phase II drugs for Idiopathic Thrombocytopenic Purpura (Immune ... U-51 in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Buy the Report ...
Ayurvedic Treatment of Idiopathic Thrombocytopenic Purpura , Ayurvedic concept of ITP ...
... Disease. Medical Tests (19). Access to Idiopathic thrombocytopenic purpura is restricted. ...
Helicobacter pylori in children with chronic idiopathic thrombocytopenic purpura : are the obstacles in the way typical in ... Helicobacter pylori in children with chronic idiopathic thrombocytopenic purpura : are the obstacles in the way typical in ...
Idiopathic Thrombocytopenic Purpura (ITP) Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder. When you have ITP, ...
Home/Idiopathic Thrombocytopenic Purpura. Idiopathic Thrombocytopenic Purpura. * Health A - Z. Natural Health NewsDecember 23, ... Idiopathic Thrombocytopenic Purpura Symptoms, Causes, Diagnosis and Treatment. What Is Idiopathic Thrombocytopenic Purpura? The ... disorder idiopathic thrombocytopenic purpura enables extreme or easy bleeding or bruising. Such bleeding tends… ...
The acronym ITP stands for Immune Thrombocytopenia and has replaced the term idiopathic Thrombocytopenic purpura. ... Herbal Treatment for ITP(Idiopathic Thrombocytopenic Purpura). Posted on December 31, 2019. December 31, 2019. By Dr. Vikram ... The acronym ITP stands for Immune Thrombocytopenia and has replaced the term idiopathic Thrombocytopenic purpura. ITP is a rare ... Immune Thrombocytopenia purpura, ITP Treatment in Ayurveda, Low Platelet Count, Treatment of Immune Thrombocytopenia purpura ...
Barre SyndromeShoulder Injury or SIRVAADEMTransverse MyelitisBrachial NeuritisAnaphylaxis Idiopathic Thrombocytopenic Purpura ( ...
SIMONATO, Luciana Estevam; MIYAHARA, Glauco Issamu BIAZOLLA, Éder Ricardo. Idiopathic thrombocytopenic purpura: importance of ... This paper presents a case report of a patient with idiopathic thrombocytopenic purpura (ITP) diagnosed in routine dental care ...
We use cookies to ensure that we give you the best experience on our website. If you click Accept all cookies well assume that you are happy to receive all cookies and you wont see this message again. If you click Reject all non-essential cookies only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click Find out more for information on how to change your cookie settings. ...
Find the best doctors for Idiopathic Thrombocytopenic Purpura (ITP) in Bahawalpur. Book in-person or online video appointments ... The fee for the top doctors for Idiopathic Thrombocytopenic Purpura (ITP) in Bahawalpur ranges from Rs. 700 to 1,000. You can ... Click here to book an appointment with top doctors for Idiopathic Thrombocytopenic Purpura (ITP) in Bahawalpur. Or, you can ... How can I book an appointment with a doctor for Idiopathic Thrombocytopenic Purpura (ITP) in Bahawalpur?. ...
title = "Idiopathic thrombocytopenic purpura: Beyond consensus",. abstract = "Idiopathic thrombocytopenic purpura (ITP) is the ... Idiopathic thrombocytopenic purpura: Beyond consensus. Together they form a unique fingerprint. * Idiopathic Thrombocytopenic ... Idiopathic thrombocytopenic purpura: Beyond consensus. / Medeiros, Desiree; Buchanan, George R. In: Current opinion in ... Idiopathic thrombocytopenic purpura: Beyond consensus. Current opinion in pediatrics. 2000 Jan 27;12(1):4-9. doi: 10.1097/ ...
Betamethasone for idiopathic thrombocytopenic purpura during pregnancy answers are found in the Evidence-Based Medicine ... purpura_during_pregnancy. Betamethasone for idiopathic thrombocytopenic purpura during pregnancy. Evidence-Based Medicine ... purpura_during_pregnancy. Betamethasone for Idiopathic Thrombocytopenic Purpura During Pregnancy [Internet]. In: Evidence-Based ... purpura_during_pregnancy. Accessed December 6, 2023.. Betamethasone for idiopathic thrombocytopenic purpura during pregnancy. ( ...
T1 - [Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and ... Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and ... Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and ... Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and ...
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls to <100 × 109/L. ... Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls to ,100 × 109/L. There are ... Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease in which the platelet count falls to ,100 × 109/L. ... The cycle starts from the idiopathic thrombocytopenic purpura (ITP) treatment state (PL ,30 × 109/L) and moves to the next ...
... the diagnosis made was thrombotic thrombocytopenic purpura-hemolytic uremic syndrome due to idiopathic combined, autoantibody- ... Due to hemolytic anemia, thrombocytopenia, and schistocytosis, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome ... Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. ... Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic ...
Idiopathic thrombocytopenic purpura (ITP) is a common acquired bleeding disorder of childhood. It may follow a viral infection ... Concurrent Celiac Disease, Idiopathic Thrombocytopenic Purpura and Autoimmune Thyroiditis: A Case Report ...
Idiopathic thrombocytopenic purpura in children: Recognition and management. David Sadowitz, Abdul Kader Souid, Thomas E. ... Dive into the research topics of Idiopathic thrombocytopenic purpura in children: Recognition and management. Together they ...
Our patient was a 64-year-old woman with a history of long-term steroid treatment for idiopathic thrombocytopenic purpura . Her ... Her past medical history included idiopathic thrombocytopenic purpura (ITP) 3 years ago that was treated with long-term ... Lafon ME, Bioulac-Sage P, Balabaud C. Hepatic fibrosis in patients with idiopathic thrombocytopenic purpura. Liver 1988;8:24-27 ... Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura. Article ...
Idiopathic Thrombocytopenic Purpura Market Segment Analysis By Geography The Idiopathic Thrombocytopenic Purpura based on ... Idiopathic Thrombocytopenic Purpura Market Segment Analysis By Category. The Idiopathic Thrombocytopenic Purpura Market based ... Idiopathic Thrombocytopenic Purpura Market Segment Analysis By Distribution Channel. The Idiopathic Thrombocytopenic Purpura ... Idiopathic Thrombocytopenic Purpura (ITP) is also known as Immune Thrombocytopenic Purpura which is demarcated as a form of ...
The child has idiopathic thrombocytopenic purpura (ITP), an acquired autoimmune disorder that results in platelet destruction. ... Answer: Immune Thrombocytopenic Purpura (ITP). *Background: *Acquired, isolated thrombocytopenia (platelet count ,100 x 103/µL ... Purpura may be divided into dry (on skin) vs. wet (hemorrhagic bullae on mucosal surfaces). Wet purpura is regarded a predictor ... Farhangi H (2016). "Clinical features and treatment outcomes of primary immune thrombocytopenic purpura in hospitalized ...
Idiopathic thrombocytopenic purpura. Dapsone is effective and safe for adjunctive glucocorticoid-sparing treatment of persons ... with idiopathic thrombocytopenic purpura and is preferred over danazol or interferon alpha in those people with antinuclear ... "Immunomodulatory treatments for persistent and chronic immune thrombocytopenic purpura: A PRISMA-compliant systematic review ... Liang SE, Hoffmann R, Peterson E, Soter NA (2019). "Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune ...
Idiopathic thrombocytopenic purpura *. Listeriosis *. Pelvic inflammatory disease, particularly if complicated by tubo-ovarian ...
Immune thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys platelets, which are necessary ... Immune thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys platelets, which are necessary ... ITP; Immune thrombocytopenia; Bleeding disorder - idiopathic thrombocytopenic purpura; Bleeding disorder - ITP; Autoimmune - ... Immune thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys platelets, which are necessary ...
HPV Vaccines and Idiopathic Thrombocytopenic Purpura. April 27, 2013. By Norma 19 Comments ... Idiopathic Thrombocytopenic Purpura (ITP). This happened just a little over a month after her second injection of Gardasil. She ...
Pardhan A, Hameed A, Zafar H, Mazahir S, Murtaza G. Outcomes of splenectomy for idiopathic thrombocytopenic purpura in adults: ... Outcomes of splenectomy for idiopathic thrombocytopenic purpura in adults : A developing country perspective. In: Journal of ... keywords = "Idiopathic Thrombocytopenic Purpura, Platelet, Predictors, Response, Splenectomy",. author = "Amyn Pardhan and ... Objective: to determine the outcome of splenectomy done in adult patients of Idiopathic Thrombocytopenic Purpura over a period ...
Idiopathic thrombocytopenic purpura. * Constitutional symptoms, such as fever (,38.5°C) or diarrhea lasting more than 1 month ...
  • Since no clinical symptoms/laboratory findings indicated a malignant or specific autoimmune-mediated disorder, the diagnosis made was thrombotic thrombocytopenic purpura-hemolytic uremic syndrome due to idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency. (biomedcentral.com)
  • IVIG was initially shown to be effective in autoimmune idiopathic thrombocytopenic purpura (ITP) in 1981. (medscape.com)
  • Helicobacter pylori in children with chronic idiopathic thrombocytopenic purpura : are the obstacles in the way typical in pediatric hematology? (unibas.ch)
  • Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs]. (psu.edu)
  • We report two patients (70- and 49-year-old Japanese men) with acute exacerbation of chronic idiopathic thrombocytopenic purpura (ITP) and deep venous thrombosis of the lower extremities. (psu.edu)
  • The Idiopathic Thrombocytopenic Purpura Market based on the Category can be further segmented into short term/acute ITP, Long term/Chronic ITP. (asianewswire.net)
  • The Acute ITP segment held the largest share in 2021 owing to the predominance of short-term ITP over the chronic idiopathic thrombocytopenic purpura. (asianewswire.net)
  • Subdural hemorrhage in a 32-year-old man with chronic idiopathic thrombocytopenic purpura. (thieme-connect.com)
  • We will also be participating in treatment and outcome trials in the treatment of chronic Idiopathic Thrombocytopenic Purpura through the ITP Consortium of North America. (uclahealth.org)
  • Indicated for thrombocytopenia associated with chronic idiopathic thrombocytopenic purpura in patients experiencing inadequate response to corticosteroids, immunoglobulins, or splenectomy. (medscape.com)
  • ABSTRACT To test the role of T helper cell Th1 immunity we recruited 24 patients with idiopathic thrombocytopenia associated with H. pylori seropositivity. (who.int)
  • Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder. (familydoctor.org)
  • Idiopathic thrombocytopenic purpura (ITP) is the most common acquired bleeding disorder encountered by pediatricians. (elsevierpure.com)
  • Idiopathic thrombocytopenic purpura (ITP) is a common acquired bleeding disorder of childhood. (bezmialem.edu.tr)
  • Immune thrombocytopenic purpura (ITP) is a bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting. (medlineplus.gov)
  • In childhood idiopathic thrombocytopenic purpura (ITP), both intravenous high-dose steroids and immunoglobulin treatments have been demonstrated to raise platelet counts reliably and in most cases within 72 h, when used as separate therapeutic modalities. (karger.com)
  • In addition to this, the term purpura is also misleading as one-third of the newly diagnosed ITP patients have no bleeding but only low platelet counts. (247healthblog.com)
  • Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. (medscape.com)
  • Objective: to determine the outcome of splenectomy done in adult patients of Idiopathic Thrombocytopenic Purpura over a period of 10 years and, secondarily, to determine the predictors of complete response to therapy. (aku.edu)
  • Methods: The retrospective review comprised of adult patients over 14 years of age who underwent open or laparoscopic splenectomy for Idiopathic Thrombocytopenic Purpura at Aga Khan University Hospital, Karachi, from January 2000 to December 2010. (aku.edu)
  • Outcome was the response to splenectomy as per new definition of response set by the American Society of Haematology 2011 evidence based practice guidelines for Idiopathic Thrombocytopenic Purpura. (aku.edu)
  • Conclusion: Response to splenectomy in adult Idiopathic Thrombocytopenic Purpura patients was comparable to reported rate in literature with relatively lower morbidity and mortality. (aku.edu)
  • Are the favorable outcomes of splenectomy predictable in patients with idiopathic thrombocytopenic purpura (ITP)? (elsevierpure.com)
  • Gene therapy is under development for the treatment of multiple myeloma and idiopathic thrombocytopenic purpura. (pharmaceutical-technology.com)
  • Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. (bvsalud.org)
  • To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. (nih.gov)
  • Dapsone is effective and safe for adjunctive glucocorticoid-sparing treatment of persons with idiopathic thrombocytopenic purpura and is preferred over danazol or interferon alpha in those people with antinuclear antibodies. (wikipedia.org)
  • The absence of high quality evidence for basic clinical dilemmas in immune thrombocytopenic purpura (ITP) underlines the need for contemporary guidelines relevant to the local treatment context. (mja.com.au)
  • Treatment of idiopathic thrombocytopenic purpura. (thieme-connect.com)
  • Borst F, Keuning JJ, van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. (medscape.com)
  • Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. (medscape.com)
  • Idiopathic Thrombocytopenic Purpura (ITP) is also known as Immune Thrombocytopenic Purpura which is demarcated as a form of blood disorder where Thrombocytopenic means a reduction in the number of blood platelets and Purpura means petechiae that are the acnes or spots of red and purple color on the skin due to seepage of blood. (asianewswire.net)
  • Petechiae, ecchymoses, and purpura are commonly found in dependent areas. (emdocs.net)
  • Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition with various etiopathogeneses. (biomedcentral.com)
  • Due to hemolytic anemia, thrombocytopenia, and schistocytosis, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome was suspected and plasma exchange therapy was initiated immediately. (biomedcentral.com)
  • Calpin C, Dick P, Poon A, Feldman W. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? (medscape.com)
  • High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. (medscape.com)
  • 2 Calderon C, Perez A. Immune thrombocytopenic purpura and intracranial haemorrhage a formidable medical challenge. (thieme-connect.com)
  • 5 Awerbuch G, Sandyk R. Intracranial haemorrhage in a 26 year-old woman with idiopathic thrombocytopenic purpura. (thieme-connect.com)
  • 6 Brenner B, Guilburd JN, Tatarsky I, Doron Y, Goldsher D. Spontaneous intracranial hemorrhage in immune thrombocytopenic purpura. (thieme-connect.com)
  • Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis. (thieme-connect.com)
  • Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis. (medscape.com)
  • Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. (medscape.com)
  • Purpura may be divided into dry (on skin) vs. wet (hemorrhagic bullae on mucosal surfaces). (emdocs.net)
  • The Idiopathic Thrombocytopenic Purpura based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. (asianewswire.net)
  • Adult idiopathic thrombocytopenic purpura. (ox.ac.uk)
  • This growth is owing to the massive increase in research and development efforts and an extensive focus on second-line medicines which will cure the serious conditions in patients, increase in immunity afflicted anomalies leading to damaged mucous membrane and ultimately into Immune Thrombocytopenic Purpura, enlarging pronounced health infrastructure around the globe as governments granting a myriad amount of riches for healthcare development. (asianewswire.net)
  • Although BCMA CAR -T therapy induces certain complications in some patients , idiopathic thrombocytopenic purpura ( ITP ) has not been reported as one of them. (bvsalud.org)
  • Ils ont été répartis en deux groupes : 12 patients souffrant d'une thrombocytopénie à médiation immunitaire (groupe 1) et 12 patients atteints d'une thrombocytopénie à médiation non immunitaire (groupe 2). (who.int)
  • Concurrent Celiac Disease, Idiopathic Th. (bezmialem.edu.tr)
  • Severe systemic course of juvenile idiopathic arthritis (Still's disease). (medicines.org.uk)
  • Penelope has a disease called idiopathic thrombocytopenic purpura. (bartleby.com)
  • The incidence of the disease in high-income mune thrombocytopenia (also called im- countries is about 3-10 per 100 000 chil- mune thrombocytopenic purpura or ITP), dren per year below 16 years of age [ 8,9 ]. (who.int)
  • ITP is a rare disorder and is caused by a dysregulation of the immune system therefore the term Idiopathic stands invalid internationally. (247healthblog.com)
  • By Norma Erickson Kirstie was only 12 years old when she was diagnosed with a rare disorder for which there is no known cure, Idiopathic Thrombocytopenic Purpura (ITP). (sanevax.org)
  • U-51 is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). (pharmaceutical-technology.com)
  • Local guidelines are needed to assist clinicians treating immune thrombocytopenic purpura (ITP) in Australia and New Zealand. (mja.com.au)
  • Tarantino MD, Buchanan GR. The pros and cons of drug therapy for immune thrombocytopenic purpura in children. (medscape.com)
  • Her past medical history included idiopathic thrombocytopenic purpura (ITP) 3 years ago that was treated with long-term corticosteroid therapy. (e-cmh.org)
  • Le présent article fait le point sur la recherche dans ce domaine, en comparant les pays à revenu faible et élevé. (who.int)
  • This paper presents a case report of a patient with idiopathic thrombocytopenic purpura (ITP) diagnosed in routine dental care. (bvsalud.org)
  • Immune thrombocytopenic purpura - current management practices. (medscape.com)
  • EMAILWIRE.COM , March 26, 2022 ) Idiopathic Thrombocytopenic Purpura Market size is estimated to reach $827 million by 2027, growing at a CAGR of 5.5% during the forecast period 2022-2027. (asianewswire.net)
  • The Idiopathic Thrombocytopenic Purpura Market based on the Distribution Channel type can be further segmented into Hospitals, Health centers, Retail Pharmacies, Drug Stores, Online Pharmacies. (asianewswire.net)
  • Here, we report a 17-year-old woman who presented with idiopathic combined autoantibody-mediated ADAMTS-13/factor H deficiency. (biomedcentral.com)
  • Therefore, the surging pervasiveness of ITP due to deteriorating immunity around the globe is set to drive the growth of the Idiopathic Thrombocytopenic Purpura Industry for the period 2022-2027. (asianewswire.net)